Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 75
Encontrada(s) 1 página(s)

Biblos-e Archivo. Repositorio Institucional de la UAM
Publication Tesis doctoral (DoctoralThesis)

Consentimiento informado en ecosistemas de investigación: preferencias y aplicabilidad

  • Sánchez González, María Carmen
Tesis Doctoral inédita leída en la Universidad Autónoma de Madrid, Facultad de Medicina, Departamento de Psiquiatría. Fecha de Lectura: 04-10-2024, Parte de los objetivos de esta tesis se han desarrollado como miembro del IIER en el grupo de trabajo Distributed and Federated Consent Control ( DFCC-W F) en el European Joint Programme on Rare Diseases ( EJP-RD) ( 2019 -2024) , que recibió financiación del programa europeo Horizonte 2020, con número de subvención N °825575.
e-Archivo. Repositorio Institucional de la Universidad Carlos III de Madrid
Publication Artículo científico (JournalArticle)

Community-driven governance of FAIRness assessment: an open issue, an open discussion [version 2; peer review: 3 approved, 1 approved with reservations]

  • Wilkinson, Mark D.
  • Sansone, Susanna-Assunta
  • Méndez Rodríguez, Eva María
  • David, Romain
  • Dennis, Richard
  • Hecker, David
  • Kleemola, Mari
  • Lacagnina, Carlo
  • Nikiforova, Anastasija
  • Castro, Leyla Jael
Although FAIR Research Data Principles are targeted at and implemented by different communities, research disciplines, and research stakeholders (data stewards, curators, etc.), there is no conclusive way to determine the level of FAIRness intended or required to make research artefacts (including, but not limited to, research data) Findable, Accessible, Interoperable, and Reusable. The FAIR Principles cover all types of digital objects, metadata, and infrastructures. However, they focus their narrative on data features that support their reusability. FAIR defines principles, not standards, and therefore they do not propose a mechanism to achieve the behaviours they describe in an attempt to be technology/implementation neutral. Various FAIR assessment metrics and tools have been designed to measure FAIRness. Unfortunately, the same digital objects assessed by different tools often exhibit widely different outcomes because of these independent interpretations of FAIR. This results in confusion among the publishers, the funders, and the users of digital research objects. Moreover, in the absence of a standard and transparent definition of what constitutes FAIR behaviours, there is a temptation to define existing approaches as being FAIR-compliant rather than having FAIR define the expected behaviours. This whitepaper identifies three high-level stakeholder categories -FAIR decision and policymakers, FAIR custodians, and FAIR practitioners - and provides examples outlining specific stakeholders' (hypothetical but anticipated) needs. It also examines possible models for governance based on the existing peer efforts, standardisation bodies, and other ways to acknowledge specifications and potential benefits. This whitepaper can serve as a starting point to foster an open discussion around FAIRness governance and the mechanism(s) that could be used to implement it, to be trusted, broadly representative, appropriately scoped, and sustainable. We invite engagement in this conversation in an open Google Group fair-assessment-governance@googlegroups.com, MDW acknowledges funds supporting his work, including the EJP RD initiative which has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement N°825575. SAS acknowledges funds that supports her, including FAIRplus (IMI 802750), EOSC-Life (H2020 EU 824087), FAIRsharing (Wellcome 212930), Precision Toxicology (H2020 EU 965406), UKRI DASH grant (MR/V038966/1), BY-COVID (Horizon EU 101046203), AgroServ (Horizon EU 10105 8020), and the ELIXIR Interoperability Platform. EM acknowledges support from the FAIRsFAIR Fostering FAIR Data Practices in Europe (funding number 831558). RD David was supported by the EOSC-Life European program under grant agreement Nº824087. LJC acknowledges support from the project NFDI4DataScience, part of the German National Research Data Infrastructure funded by the Joint Science Conference (GWK) and the German Research Foundation (DFG), funding number NFDI 34/1.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Beacon v2 and Beacon networks: A "lingua franca" for federated data discovery in biomedical genomics, and beyond

  • Rambla de Argila, Jordi
  • Baudis, Michael
  • Ariosa, Roberto
  • Beck, Timothy
  • Fromont, Lauren A.
  • Navarro i Cuartiellas, Arcadi, 1969-
  • Paloots, Rahel
  • Rueda, Manuel
  • Saunders, Gary
  • Singh, Babita, 1986-
  • Spalding, J. Dylan
  • Törnoos, Juha
  • Vasallo, Claudia
  • Veal, Colin D.
  • Brookes, Anthony J.
Beacon is a basic data discovery protocol issued by the Global Alliance for Genomics and Health (GA4GH). The main goal addressed by version 1 of the Beacon protocol was to test the feasibility of broadly sharing human genomic data, through providing simple "yes" or "no" responses to queries about the presence of a given variant in datasets hosted by Beacon providers. The popularity of this concept has fostered the design of a version 2, that better serves real-world requirements and addresses the needs of clinical genomics research and healthcare, as assessed by several contributing projects and organizations. Particularly, rare disease genetics and cancer research will benefit from new case level and genomic variant level requests and the enabling of richer phenotype and clinical queries as well as support for fuzzy searches. Beacon is designed as a "lingua franca" to bridge data collections hosted in software solutions with different and rich interfaces. Beacon version 2 works alongside popular standards like Phenopackets, OMOP, or FHIR, allowing implementing consortia to return matches in beacon responses and provide a handover to their preferred data exchange format. The protocol is being explored by other research domains and is being tested in several international projects., This study was funded by ELIXIR, the research infrastructure for lifescience data and also by La Caixa Foundation (grant number 004745/ 008034). Tim Beck was supported by a UKRI Innovation Fellowship at Health Data Research UK (MR/S003703/1). Anthony J. Brookes and Jordi Rambla were supported, in part, by the European Union's Horizon 2020 research and innovation program under the EJP RD COFUND‐EJP #825575. Michael Baudis acknowledges funding under the BioMedIT Network project of Swiss Institute of Bioinformatics (SIB) and Swiss Personalized Health Network (SPHN)
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Position paper on management of personal data in environment and health research in Europe

  • Govarts, Eva
  • Gilles, Liese
  • Bopp, Stephanie
  • Holub, Petr
  • Matalonga, Leslie
  • Vermeulen, Roel
  • Vrijheid, Martine
  • Beltran, Sergi
  • Hartlev, Mette
  • Jones, Sarah
  • Rodriguez Martin, Laura
  • Standaert, Arnout
  • Swertz, Morris A.
  • Theunis, Jan
  • Trier, Xenia
  • Vogel, Nina
  • Van Espen, Koert
  • Remy, Sylvie
  • Schoeters, Greet
Management of datasets that include health information and other sensitive personal information of European study participants has to be compliant with the General Data Protection Regulation (GDPR, Regulation (EU) 2016/679). Within scientific research, the widely subscribed'FAIR' data principles should apply, meaning that research data should be findable, accessible, interoperable and re-usable. Balancing the aim of open science driven FAIR data management with GDPR compliant personal data protection safeguards is now a common challenge for many research projects dealing with (sensitive) personal data. In December 2020 a workshop was held with representatives of several large EU research consortia and of the European Commission to reflect on how to apply the FAIR data principles for environment and health research (E&H). Several recent data intensive EU funded E&H research projects face this challenge and work intensively towards developing solutions to access, exchange, store, handle, share, process and use such sensitive personal data, with the aim to support European and transnational collaborations. As a result, several recommendations, opportunities and current limitations were formulated. New technical developments such as federated data management and analysis systems, machine learning together with advanced search software, harmonized ontologies and data quality standards should in principle facilitate the FAIRification of data. To address ethical, legal, political and financial obstacles to the wider re-use of data for research purposes, both specific expertise and underpinning infrastructure are needed. There is a need for the E&H research data to find their place in the European Open Science Cloud. Communities using health and population data, environmental data and other publicly available data have to interconnect and synergize. To maximize the use and re-use of environment and health data, a dedicated supporting European infrastructure effort, such as the EIRENE research infrastructure within the ESFRI roadmap 2021, is needed that would interact with existing infrastructures., HBM4EU is co-financed under Horizon 2020 (grant agreement No 733032). EUCAN-Connect is funded by the European Commission within the call topic SC1-BHC-05-2018: “International flagship collaboration with Canada for human data storage, integration and sharing to enable personalized medicine approaches” (Grant Agreement No 824989). The Canadian project partners have been funded by the Canadian Institutes of Health Research (CIHR) and the Fonds de recherche du Québec – Santé. The LifeCycle project received funding from the European Union’s Horizon 2020 research and innovation programme (Grant Agreement No. 733206 LifeCycle). The HELIX project received funding from the European Community’s Seventh Framework Programme (grant agreement no 308333 HELIX). ISGlobal acknowledges support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019-2023” Program (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Program. Roel Vermeulen is supported by EXPOSOME-NL and EXPANSE. EXPOSOME-NL is funded through the Gravitation program of the Dutch Ministry of Education, Culture, and Science and the Netherlands Organization for Scientific Research (NWO grant number 024.004.017). EXPANSE has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 874627. EOSC-Life project supported by EU Horizon 2020, grant agreement no. 824087. EJP-RD and Solve-RD projects have been financed under Horizon 2000 (grant numbers H2020 779257 and H2020 825575).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Remote visualization of large-scale genomic alignments for collaborative clinical research and diagnosis of rare diseases

  • Corvò, Alberto
  • Matalonga, Leslie
  • Laurie, Steven, 1973-
  • Picó-Amador, Daniel
  • Fernández Callejo, Marcos
  • Paramonov, Ida
  • Gut, Ivo Glynne
  • Piscia, Davide
  • Beltran, Sergi
The Solve-RD project objectives include solving undiagnosed rare diseases (RD) through collaborative research on shared genome-phenome datasets. The RD-Connect Genome-Phenome Analysis Platform (GPAP), for data collation and analysis, and the European Genome-Phenome Archive (EGA), for file storage, are two key components of the Solve-RD infrastructure. Clinical researchers can identify candidate genetic variants within the RD-Connect GPAP and, thanks to the developments presented here as part of joint ELIXIR activities, are able to remotely visualize the corresponding alignments stored at the EGA. The Global Alliance for Genomics and Health (GA4GH) htsget streaming application programming interface (API) is used to retrieve alignment slices, which are rendered by an integrated genome viewer (IGV) instance embedded in the GPAP. As a result, it is no longer necessary for over 11,000 datasets to download large alignment files to visualize them locally. This work highlights the advantages, from both the user and infrastructure perspectives, of implementing interoperability standards for establishing federated genomics data networks., This study was partially funded by ELIXIR Implementation Studies “Remote real-time visualization of human RDs genomics data (RD-Connect) stored at the EGA ELIXIR” (2017–2018), “Integration of ELIXIR-IIB in ELIXIR Rare Disease activities (2017–2018),” and “Rare Disease Infrastructure ELIXIR (2019–2020)” and the Solve-RD project, which received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement no. 779257. Data were analyzed using the RD-Connect Genome-Phenome Analysis Platform, which has received funding from EU projects RD-Connect, Solve-RD, and EJP-RD (grant nos. FP7 305444, H2020 779257, and H2020 825575), Instituto de Salud Carlos III (grant nos. PT13/0001/0044 and PT17/0009/0019; Instituto Nacional de Bioinformática, INB), and ELIXIR Implementation Studies. We acknowledge the support of the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Solving patients with rare diseases through programmatic reanalysis of genome-phenome data

  • Matalonga, Leslie
  • Hernández Ferrer, Carles
  • Piscia, Davide
  • Tonda, Raúl
  • Laurie, Steven, 1973-
  • Fernández Callejo, Marcos
  • Picó, Daniel
  • Garcia-Linares, Carles
  • Papakonstantinou, Anastasios
  • Corvò, Alberto
  • Joshi, Ricky S.
  • Diez, Hector
  • Gut, Ivo Glynne
  • Beltran, Sergi
  • Solve-RD Consortium
Reanalysis of inconclusive exome/genome sequencing data increases the diagnosis yield of patients with rare diseases. However, the cost and efforts required for reanalysis prevent its routine implementation in research and clinical environments. The Solve-RD project aims to reveal the molecular causes underlying undiagnosed rare diseases. One of the goals is to implement innovative approaches to reanalyse the exomes and genomes from thousands of well-studied undiagnosed cases. The raw genomic data is submitted to Solve-RD through the RD-Connect Genome-Phenome Analysis Platform (GPAP) together with standardised phenotypic and pedigree data. We have developed a programmatic workflow to reanalyse genome-phenome data. It uses the RD-Connect GPAP's Application Programming Interface (API) and relies on the big-data technologies upon which the system is built. We have applied the workflow to prioritise rare known pathogenic variants from 4411 undiagnosed cases. The queries returned an average of 1.45 variants per case, which first were evaluated in bulk by a panel of disease experts and afterwards specifically by the submitter of each case. A total of 120 index cases (21.2% of prioritised cases, 2.7% of all exome/genome-negative samples) have already been solved, with others being under investigation. The implementation of solutions as the one described here provide the technical framework to enable periodic case-level data re-evaluation in clinical settings, as recommended by the American College of Medical Genetics., The Solve-RD project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779257. Data were analysed using the RD‐Connect Genome‐Phenome Analysis Platform, which received funding from EU projects RD‐Connect, Solve-RD and EJP-RD (grant numbers FP7 305444, H2020 779257, H2020 825575), Instituto de Salud Carlos III (grant numbers PT13/0001/0044, PT17/0009/0019; Instituto Nacional de Bioinformática, INB) and ELIXIR Implementation Studies.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Solving unsolved rare neurological diseases-a Solve-RD viewpoint

  • Matalonga, Leslie
  • Timmann, Dagmar
  • Erasmus, Corrie E.
  • Reichbauer, Jennifer
  • Wayand, Melanie
  • Solve-RD-DITF-RND
  • van de Warrenburg, Bart
  • Schöls, Ludger
  • Wilke, Carlo
  • Bevot, Andrea
  • Zuchner, Stephan
  • Beltran, Sergi
  • Laurie, Steven, 1973-
  • Matalonga, Leslie
  • Graessner, Holm
  • Synofzik, Matthis
  • Solve-RD Consortium
Rare genetic neurological disorders (RND; ORPHA:71859) are a heterogeneous group of disorders comprising >1700 distinct genetic disease entities. However, genetic discoveries have not yet translated into dramatic increases of diagnostic yield and indeed rates of molecular genetic diagnoses have been stuck at about 30–50% across NGS modalities and RND phenotypes [1, 2]. Existence of yet unknown disease genes as well as shortcomings of commonly employed NGS technologies and analysis pipelines in detecting certain variant types are typically cited to explain the low diagnosis rates. To increase the diagnostic yield in RNDs - one of the four focus disease groups in Solve-RD - we follow two major approaches, that we will here present and exemplify: (i) systematic state-of the art re-analysis of large cohorts of unsolved whole-exome/genome sequencing (WES/WGS) RND datasets; and (ii) novel-omics approaches. Based on the way Solve-RD systematically organizes researchers’ expertise to channel this approach [3], the European Reference Network for Rare Neurological Diseases (ERN-RND) has established its own Data Interpretation Task Force (DITF) within SOLVE-RD, which is currently composed of clinical and genetic experts from 29 sites in 15 European countries., The Solve-RD project has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No. 779257. Data were analysed using the RD‐Connect Genome‐Phenome Analysis Platform, which received funding from EU projects RD‐Connect, Solve-RD and EJP-RD (Grant Numbers FP7 305444, H2020 779257, H2020 825575), Instituto de Salud Carlos III (Grant Numbers PT13/0001/0044, PT17/0009/0019; Instituto Nacional de Bioinformática, INB) and ELIXIR Implementation Studies. The study was further funded by the Federal Ministry of Education and Research, Germany, through the TreatHSP network (01GM1905 to RS and LS), the National Institute of Neurological Diseases and Stroke (R01NS072248 to SZ and RS), the European Joint Program on Rare Diseases-EJP-RD COFUND-EJP N° 825575 through funding for the PROSPAX consortium (441409627 to MS, RS and BvW). CW was supported by the PATE program of the Medical Faculty, University of Tübingen. CEE received support from the Dutch Princess Beatrix Muscle Fund and the Dutch Spieren voor Spieren Muscle fund. Authors on this paper are members of the European Reference Network for Rare Neurological Diseases (ERN-RND, Project ID 739510)
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The European Genome-phenome Archive in 2021

  • Freeberg, Mallory Ann
  • Fromont, Lauren A.
  • D'Altri, Teresa, 1984-
  • Jene, Aina
  • Moldes, Mauricio
  • Ariosa, Roberto
  • Fernández-Orth, Dietmar
  • Haziza, Frédéric
  • Martinez Llobet, Oscar
  • Milla, Gemma
  • Rueda, Manuel
  • Singh, Babita, 1986-
  • Torre, Sabela de la
  • Uyan, Umuthan
  • Vasallo, Claudia
  • Guigó Serra, Roderic
  • Navarro i Cuartiellas, Arcadi, 1969-
  • Rambla de Argila, Jordi
The European Genome-phenome Archive (EGA - https://ega-archive.org/) is a resource for long term secure archiving of all types of potentially identifiable genetic, phenotypic, and clinical data resulting from biomedical research projects. Its mission is to foster hosted data reuse, enable reproducibility, and accelerate biomedical and translational research in line with the FAIR principles. Launched in 2008, the EGA has grown quickly, currently archiving over 4,500 studies from nearly one thousand institutions. The EGA operates a distributed data access model in which requests are made to the data controller, not to the EGA, therefore, the submitter keeps control on who has access to the data and under which conditions. Given the size and value of data hosted, the EGA is constantly improving its value chain, that is, how the EGA can contribute to enhancing the value of human health data by facilitating its submission, discovery, access, and distribution, as well as leading the design and implementation of standards and methods necessary to deliver the value chain. The EGA has become a key GA4GH Driver Project, leading multiple development efforts and implementing new standards and tools, and has been appointed as an ELIXIR Core Data Resource., Horizon 2020 Programme of the European Union [CORBEL [654248], ELIXIR-EXCELERATE [676559], Solve-RD [779257], EASI-Genomics [824110], EJP-RD [825575], CINECA [825775], EuCanCan [825835], EUCanshare [825903], ELIXIR-CONVERGE [871075]]; Wellcome Trust Global Alliance for Genomics and Health [201535/Z/16/Z]; UK Biobank; Chan Zuckerberg Initiative DAF, an advised fund of Silicon Valley Community Foundation [2017-171304 (5022)]; European Molecular Biology Laboratory (EMBL); LaCaixa Foundation [004745/008034]; [LCF/PR/CE20/50740008]. Funding for open access charge: LaCaixa Foundation [LCF/PR/CE20/50740008].
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The data use ontology to streamline responsible access to human biomedical datasets

  • Lawson, Jonathan
  • Jene, Aina
  • Rambla de Argila, Jordi
  • Courtot, Mélanie
Human biomedical datasets that are critical for research and clinical studies to benefit human health also often contain sensitive or potentially identifying information of individual participants. Thus, care must be taken when they are processed and made available to comply with ethical and regulatory frameworks and informed consent data conditions. To enable and streamline data access for these biomedical datasets, the Global Alliance for Genomics and Health (GA4GH) Data Use and Researcher Identities (DURI) work stream developed and approved the Data Use Ontology (DUO) standard. DUO is a hierarchical vocabulary of human and machine-readable data use terms that consistently and unambiguously represents a dataset's allowable data uses. DUO has been implemented by major international stakeholders such as the Broad and Sanger Institutes and is currently used in annotation of over 200,000 datasets worldwide. Using DUO in data management and access facilitates researchers' discovery and access of relevant datasets. DUO annotations increase the FAIRness of datasets and support data linkages using common data use profiles when integrating the data for secondary analyses. DUO is implemented in the Web Ontology Language (OWL) and, to increase community awareness and engagement, hosted in an open, centralized GitHub repository. DUO, together with the GA4GH Passport standard, offers a new, efficient, and streamlined data authorization and access framework that has enabled increased sharing of biomedical datasets worldwide., G.K., M.A.F., H.P., J.D.S., and M.C. were funded by EMBL-EBI Core Funds and Wellcome Trust GA4GH award number 201535/Z/16/Z. T. T. Boughtwood was funded by NHMRC GNT111353, GNT200001, and the Australian MRFF. P.A. was funded by ELIXIR Luxembourg. S.D. and K.R. were funded by the Broad Institute. M.A.H. and M.B. received funding from NIH #5R24OD011883. M.L. and M.C. were funded by the CINECA project (H2020 No 825775). N.M. and L.Z. were funded by H3ABioNet, NIH grant number U24HG006941. S.O. and C.Y. received funding from the Japan Agency for Medical Research and Development (AMED) under grant numbers JP19kk020501 and JP18kk0205012. A.A.P. was funded by NHGRI AnVIL, award number U24HG010262. F.P. was supported, in part, by the European Union’s Horizon 2020 research and innovation program under the EJP RD COFUND-EJP #825575. M.A.S. and E.J.v.E. were funded by FAIR genomes (ZonMW #846003201) and EOSC-Life (H2020 #824087)
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Increasing phenotypic annotation improves the diagnostic rate of exome sequencing in a rare neuromuscular disorder

  • Thompson, Rachel
  • Papakonstantinou, Anastasios
  • Beltran, Sergi
  • Topf, Ana
  • de Paula Estephan, Eduardo
  • Poloavarapu, Kiran
  • Hoen, Peter A. C.
  • Missier, Paolo
  • Lochmüller, Hanns
Phenotype-based filtering and prioritization contribute to the interpretation of genetic variants detected in exome sequencing. However, it is currently unclear how extensive this phenotypic annotation should be. In this study, we compare methods for incorporating phenotype into the interpretation process and assess the extent to which phenotypic annotation aids prioritization of the correct variant. Using a cohort of 29 patients with congenital myasthenic syndromes with causative variants in known or newly discovered disease genes, exome data and the Human Phenotype Ontology (HPO)-coded phenotypic profiles, we show that gene-list filters created from phenotypic annotations perform similarly to curated disease-gene virtual panels. We use Exomiser, a prioritization tool incorporating phenotypic comparisons, to rank candidate variants while varying phenotypic annotation. Analyzing 3,712 combinations, we show that increasing phenotypic annotation improved prioritization of the causative variant, from 62% ranked first on variant alone to 90% with seven HPO annotations. We conclude that any HPO-based phenotypic annotation aids variant discovery and that annotation with over five terms is recommended in our context. Although focused on a constrained cohort, this provides real-world validation of the utility of phenotypic annotation for variant prioritization. Further research is needed to extend this concept to other diseases and more diverse cohorts., Data was analyzed using the RD‐Connect Genome‐Phenome Analysis Platform developed under the 2012‐2018 FP7‐funded project RD‐ Connect (Grant Agreement No.: 305444). R. T., S. B., A. P. N., P. tH., and H. L. received support from the EU FP7 projects 305444 (RD‐ Connect) and 305121 (NeurOmics). S. B. received support from the EU FP7 project 313010 (BBMRI‐LPC). S. B. and P. tH. received support from the EU Horizon 2020 project 779257 (Solve‐RD). S. B., P. tH., and H. L. received support from the EU Horizon 2020 project 825575 (EJP‐RD). H. L. is supported by a project grant of the Canadian Institutes of Health Research (CIHR PJT 162265)
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A Solve-RD ClinVar-based reanalysis of 1522 index cases from ERN-ITHACA reveals common pitfalls and misinterpretations in exome sequencing

  • Denommé-Pichon, Anne-Sophie
  • Matalonga, Leslie
  • Faivre, Laurence
Purpose: Within the Solve-RD project (https://solve-rd.eu/), the European Reference Network for Intellectual disability, TeleHealth, Autism and Congenital Anomalies aimed to investigate whether a reanalysis of exomes from unsolved cases based on ClinVar annotations could establish additional diagnoses. We present the results of the "ClinVar low-hanging fruit" reanalysis, reasons for the failure of previous analyses, and lessons learned. Methods: Data from the first 3576 exomes (1522 probands and 2054 relatives) collected from European Reference Network for Intellectual disability, TeleHealth, Autism and Congenital Anomalies was reanalyzed by the Solve-RD consortium by evaluating for the presence of single-nucleotide variant, and small insertions and deletions already reported as (likely) pathogenic in ClinVar. Variants were filtered according to frequency, genotype, and mode of inheritance and reinterpreted. Results: We identified causal variants in 59 cases (3.9%), 50 of them also raised by other approaches and 9 leading to new diagnoses, highlighting interpretation challenges: variants in genes not known to be involved in human disease at the time of the first analysis, misleading genotypes, or variants undetected by local pipelines (variants in off-target regions, low quality filters, low allelic balance, or high frequency). Conclusion: The "ClinVar low-hanging fruit" analysis represents an effective, fast, and easy approach to recover causal variants from exome sequencing data, herewith contributing to the reduction of the diagnostic deadlock., The Solve-RD project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement number 779257. Data were analyzed using the RD-Connect Genome-Phenome Analysis Platform, which received funding from the EU projects RD-Connect, Solve-RD, and European Joint Programme on Rare Diseases (grant numbers FP7 305444, H2020 779257, H2020 825575), Instituto de Salud Carlos III (grant numbers PT13/0001/0044, PT17/0009/0019; Instituto Nacional de Bioinformática), and ELIXIR Implementation Studies. The collaborations in this study were facilitated by the European Reference Network for Intellectual disability, TeleHealth, Autism and Congenital Anomalies, one of the 24 European Reference Networks approved by the European Reference Network Board of Member States, cofunded by the European Commission. This project was supported by the Czech Ministry of Health (number 00064203) and by the Czech Ministry of Education, Youth and Sports (number - LM2018132) to M.M.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Standards of NGS data sharing and analysis in Ataxias: recommendations by the NGS Working Group of the Ataxia Global Initiative

  • Beijer, Danique
  • Fogel, Brent L.
  • Beltran, Sergi
  • Danzi, Matt C.
  • Németh, Andrea H.
  • Züchner, Stephan
  • Synofzik, Matthis
  • AGI Ataxia NGS genomics, platforms Working Group
The Ataxia Global Initiative (AGI) is a worldwide multi-stakeholder research platform to systematically enhance trial-readiness in degenerative ataxias. The next-generation sequencing (NGS) working group of the AGI aims to improve methods, platforms, and international standards for ataxia NGS analysis and data sharing, ultimately allowing to increase the number of genetically ataxia patients amenable for natural history and treatment trials. Despite extensive implementation of NGS for ataxia patients in clinical and research settings, the diagnostic gap remains sizeable, as approximately 50% of patients with hereditary ataxia remain genetically undiagnosed. One current shortcoming is the fragmentation of patients and NGS datasets on different analysis platforms and databases around the world. The AGI NGS working group in collaboration with the AGI associated research platforms—CAGC, GENESIS, and RD-Connect GPAP—provides clinicians and scientists access to user-friendly and adaptable interfaces to analyze genome-scale patient data. These platforms also foster collaboration within the ataxia community. These efforts and tools have led to the diagnosis of > 500 ataxia patients and the discovery of > 30 novel ataxia genes. Here, the AGI NGS working group presents their consensus recommendations for NGS data sharing initiatives in the ataxia field, focusing on harmonized NGS variant analysis and standardized clinical and metadata collection, combined with collaborative data and analysis tool sharing across platforms., Open Access funding enabled and organized by Projekt DEAL. This work was supported by the Horizon 2020 research and innovation programme (grant 779257 Solve-RD to MS and SB), and the European Joint Programme on Rare Diseases (grant 825575 EJP RD to SB) under the EJP RD COFUND-EJP No. 825575 (PROSPAX consortium, to MS and—as an associated partner—SZ). DB is supported by a Postdoctoral Fellowship from the Alexander von Humboldt Foundation.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A mosaic PIK3CA variant in a young adult with diffuse gastric cancer: case report

  • Te Paske, Iris B.A.W.
  • Garcia-Pelaez, José
  • Sommer, Anna K.
  • Matalonga, Leslie
  • Starzynska, Teresa
  • Jakubowska, Anna
  • Solve-RD-GENTURIS group
  • van der Post, Rachel S.
  • Lubinski, Jan
  • Oliveira, Carla
  • Hoogerbrugge, Nicoline
  • de Voer, Richarda M.
Hereditary diffuse gastric cancer (HDGC) is associated with germline deleterious variants in CDH1 and CTNNA1. The majority of HDGC-suspected patients are still genetically unresolved, raising the need for identification of novel HDGC predisposing genes. Under the collaborative environment of the SOLVE-RD consortium, re-analysis of whole-exome sequencing data from unresolved gastric cancer cases (n = 83) identified a mosaic missense variant in PIK3CA in a 25-year-old female with diffuse gastric cancer (DGC) without familial history for cancer. The variant, c.3140A>G p.(His1047Arg), a known cancer-related somatic hotspot, was present at a low variant allele frequency (18%) in leukocyte-derived DNA. Somatic variants in PIK3CA are usually associated with overgrowth, a phenotype that was not observed in this patient. This report highlights mosaicism as a potential, and understudied, mechanism in the etiology of DGC., The Solve-RD project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779257. The research work at i3S/Ipatimup is supported by the European Regional Development Fund (ERDF) through COMPETE 2020 - Operacional Programme for Competitiveness and Internationalisation (POCI), Portugal 2020, and by Portuguese funds through FCT/ Ministério da Ciência, Tecnologia e Inovação in the framework of the project “Institute for Research and Innovation in Health Sciences” (POCI-01-0145-FEDER-007274) and Project Ref. POCI-01-0145-FEDER-030164. Data was reanalysed using the RD‐Connect Genome‐Phenome Analysis Platform, which received funding from EU projects RD‐Connect, Solve-RD and EJP-RD (grant numbers FP7 305444, H2020 779257, H2020 825575), Instituto de Salud Carlos III (grant numbers PT13/0001/0044, PT17/0009/0019; Instituto Nacional de Bioinformática, INB) and ELIXIR Implementation Studies.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Improved diagnosis of rare disease patients through systematic detection of runs of homozygosity

  • Matalonga, Leslie
  • Laurie, Steven, 1973-
  • Papakonstantinou, Anastasios
  • Piscia, Davide
  • Mereu, Elisabetta
  • Bullich, Gemma
  • Thompson, Rachel
  • Horvath, Rita
  • Pérez Jurado, Luis Alberto
  • Riess, Olaf
  • Gut, Ivo Glynne
  • van Ommen, Gert-Jan
  • Lochmüller, Hanns
  • Beltran, Sergi
  • RD–Connect Genome-Phenome Analysis Platform and URD-Cat Data Contributors
Autozygosity is associated with an increased risk of genetic rare disease, thus being a relevant factor for clinical genetic studies. More than 2400 exome sequencing data sets were analyzed and screened for autozygosity on the basis of detection of >1 Mbp runs of homozygosity (ROHs). A model was built to predict if an individual is likely to be a consanguineous offspring (accuracy, 98%), and probability of consanguinity ranges were established according to the total ROH size. Application of the model resulted in the reclassification of the consanguinity status of 12% of the patients. The analysis of a subset of 79 consanguineous cases with the Rare Disease (RD)-Connect Genome-Phenome Analysis Platform, combining variant filtering and homozygosity mapping, enabled a 50% reduction in the number of candidate variants and the identification of homozygous pathogenic variants in 41 patients, with an overall diagnostic yield of 52%. The newly defined consanguinity ranges provide, for the first time, specific ROH thresholds to estimate inbreeding within a pedigree on disparate exome sequencing data, enabling confirmation or (re)classification of consanguineous status, hence increasing the efficiency of molecular diagnosis and reporting on secondary consanguinity findings, as recommended by American College of Medical Genetics and Genomics guidelines., Supported by European Union projects RD-Connect, Solve-RD, and European Joint Programme of Rare Diseases (EJP-RD) grants FP7 305444, H2020 779257, and H2020 825575; Instituto de Salud Carlos III grants PT13/0001/0044 and PT17/0009/0019; Instituto Nacional de Bioinformática; ELIXIR Implementation Studies; European Union projects BBMRI-LPC EU FP7 313010, NeurOmics EU FP7 305121, and Undiagnosed Rare Disease Program of Catalonia (Departament de Salut, Generalitat de CatalunyaSLT002/16/00174); Canadian Institutes of Health Research Foundation grant FDN-167281 (H.L.); the European Research Council309548 (R.H.); the Wellcome Investigator Award 109915/Z/15/Z (R.H.); the Medical Research Council (United Kingdom) MR/N025431/1 (R.H.); the Wellcome Trust Pathfinder Scheme 201064/Z/16/Z (R.H. and H.L.); the Newton Fund (United Kingdom/Turkey) MR/N027302/1 (R.H. and H.L.); the Spanish Ministry of Economy, Industry and Competitiveness to the European Molecular Biology Laboratory (EMBL) partnership; the Centro de Excelencia Severo Ochoa; the Centres de Recerca de Catalunya (CERCA) Program/Generalitat de Catalunya; the Generalitat de Catalunya through the Department of Health and Department of Business and Knowledge; the Spanish Ministry of Economy, Industry and Competitiveness with funds from the European Regional Development Fund corresponding to the 2014 to 2020 Smart Growth Operating Program.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Twelve quick tips for deploying a Beacon

  • Fromont, Lauren A.
  • Moldes, Mauricio
  • Baudis, Michael
  • Brookes, Anthony J.
  • Navarro, Arcadi
  • Rambla de Argila, Jordi
This study was funded by ELIXIR, the research infrastructure for life-science data. The project leading to these results has also received funding and grant support from the “LaCaixa” Foundation under the Grant 004745/008034. LAF was supported, in part, by La Marató TV3, and has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101057182. AJB and JR received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 825575. MB acknowledges funding under the BioMedIT Network project of Swiss Institute of Bioinformatics (SIB) and Swiss Personalized Health Network (SPHN). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The RD-Connect Genome-Phenome Analysis Platform: Accelerating diagnosis, research, and gene discovery for rare diseases

  • Laurie, Steven, 1973-
  • Piscia, Davide
  • Matalonga, Leslie
  • Corvò, Alberto
  • Fernández Callejo, Marcos
  • Garcia-Linares, Carles
  • Hernandez-Ferrer, Carles, 1987-
  • Luengo, Cristina
  • Martínez, Inés
  • Papakonstantinou, Anastasios
  • Picó-Amador, Daniel
  • Protasio, Joan
  • Tonda, Raúl
  • Bayés, Mònica
  • Bullich, Gemma
  • Camps-Puchadas, Jordi
  • Paramonov, Ida
  • Trotta, Jean-Remi
  • Pérez Jurado, Luis Alberto
  • Rambla de Argila, Jordi
  • Gut, Ivo Glynne
  • Lochmüller, Hanns
  • Beltran, Sergi
Rare disease patients are more likely to receive a rapid molecular diagnosis nowadays thanks to the wide adoption of next-generation sequencing. However, many cases remain undiagnosed even after exome or genome analysis, because the methods used missed the molecular cause in a known gene, or a novel causative gene could not be identified and/or confirmed. To address these challenges, the RD-Connect Genome-Phenome Analysis Platform (GPAP) facilitates the collation, discovery, sharing, and analysis of standardized genome-phenome data within a collaborative environment. Authorized clinicians and researchers submit pseudonymised phenotypic profiles encoded using the Human Phenotype Ontology, and raw genomic data which is processed through a standardized pipeline. After an optional embargo period, the data are shared with other platform users, with the objective that similar cases in the system and queries from peers may help diagnose the case. Additionally, the platform enables bidirectional discovery of similar cases in other databases from the Matchmaker Exchange network. To facilitate genome-phenome analysis and interpretation by clinical researchers, the RD-Connect GPAP provides a powerful user-friendly interface and leverages tens of information sources. As a result, the resource has already helped diagnose hundreds of rare disease patients and discover new disease causing genes., We acknowledge the support of the developers of PhenoTips, which was used in the past by RD-Connect and NeurOmics as the primary tool to collate phenotypic data. We would also like to thank the leaders and members of the Instituto Nacional de Bioinformática (INB) and ELIXIR for their support and collaboration throughout the years. RD-Connect (RD-Connect, an integrated platform connecting registries, biobanks, and clinical bioinformatics) received funding from the Seventh Framework (FP7) Programme of the European Union under grant agreement No 305444. Data were analyzed using the RD-Connect GPAP, which received funding from EU projects Solve-RD, EJP-RD (grant numbers H2020 779257, H2020 825575), Instituto de Salud Carlos III (Grant numbers PT13/0001/0044, PT17/0009/0019; Instituto Nacional de Bioinformática, INB), ELIXIR-EXCELERATE (Grant number EU H2020 #676559) and ELIXIR Implementation Studies (Remote real-time visualization of human rare disease genomics data (RD-Connect) stored at the EGA ELIXIR. 2017-2018; ELIXIR IT-2017-INTEGRATION, Rare Disease Infrastructure ELIXIR, 2019-2020 and the Beacon ELIXIR, 2019-2021). The RD-Connect GPAP has leveraged developments funded through project VEIS (001-P-001647 co-financed by the European Regional Development Fund of the European Union in the framework of the Operational Program FEDER of Catalonia 2014-2020 with the support of the Secretaria d'Universitats i Recerca del Departament d'Empresa i Coneixement de la Generalitat de Catalunya) and URD-Cat (PERIS SLT002/16/00174, Departament de Salut, Generalitat de Catalunya). The research leading to these results has received funding from Consequitur (Newton Fund UK/Turkey, MR/N027302/1), BBMRI-LPC (EU FP7 #313010), NeurOmics (EU FP7 #305121), the Economic Development Department of the Navarra Government (Grant number 001114112017), the European Reference Network for Rare Neurological Diseases (Project ID number 739510) and NIH, National Institute of Child Health and Human Development (1R01HD103805-01). We acknowledge the support of the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Program/Generalitat de Catalunya. We also acknowledge the support of the Generalitat de Catalunya through Departament de Salut and Departament d'Empresa i Coneixement and Co-financing by the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) with funds from the European Regional Development Fund (ERDF) corresponding to the 2014-2020 Smart Growth Operating Program. HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Systematic collaborative reanalysis of genomic data improves diagnostic yield in neurologic rare diseases

  • Bullich, Gemma
  • Matalonga, Leslie
  • Pujadas, Montserrat
  • Papakonstantinou, Anastasios
  • Piscia, Davide
  • Tonda, Raúl
  • González, Juan Ramón
  • Laurie, Steven, 1973-
  • Luengo, Cristina
  • Ovelleiro, David
  • Parra Farré, Genís
  • Pérez Jurado, Luis Alberto
  • Beltran, Sergi
  • Undiagnosed Rare Disease Program of Catalonia (URD-Cat) Consortium
Many patients experiencing a rare disease remain undiagnosed even after genomic testing. Reanalysis of existing genomic data has shown to increase diagnostic yield, although there are few systematic and comprehensive reanalysis efforts that enable collaborative interpretation and future reinterpretation. The Undiagnosed Rare Disease Program of Catalonia project collated previously inconclusive good quality genomic data (panels, exomes, and genomes) and standardized phenotypic profiles from 323 families (543 individuals) with a neurologic rare disease. The data were reanalyzed systematically to identify relatedness, runs of homozygosity, consanguinity, single-nucleotide variants, insertions and deletions, and copy number variants. Data were shared and collaboratively interpreted within the consortium through a customized Genome-Phenome Analysis Platform, which also enables future data reinterpretation. Reanalysis of existing genomic data provided a diagnosis for 20.7% of the patients, including 1.8% diagnosed after the generation of additional genomic data to identify a second pathogenic heterozygous variant. Diagnostic rate was significantly higher for family-based exome/genome reanalysis compared with singleton panels. Most new diagnoses were attributable to recent gene-disease associations (50.8%), additional or improved bioinformatic analysis (19.7%), and standardized phenotyping data integrated within the Undiagnosed Rare Disease Program of Catalonia Genome-Phenome Analysis Platform functionalities (18%)., Supported by Generalitat de Catalunya through Departament de Salut (SLT002/16/00174 to URD-Cat consortium) and Departament d’Empresa i Coneixement and the CERCA Program; FP7 and H2020 EU projects RD-Connect, Solve-RD, and EJP-RD grants FP7 305444, H2020 779257, and H2020 825575 for CNAG-CRG; Spanish Ministry of Science and Innovation to the EMBL partnership and through the Instituto de Salud Carlos III grants PT13/0001/0044 and PT17/0009/0019 for CNAG-CRG and grants PI16/01048, PI19/01310, PI18/00451, PI18/00498, and PI21/00935 for IDIBAPS (Instituto Nacional de Bioinformática); ELIXIR Implementation Studies (CNAG-CRG); Centro de Investigaciones Biomédicas en Red de Enfermedades Raras; Centro de Excelencia Severo Ochoa grant SEV-2016-0571 (CNAG-CRG) and grant CEX 2018-000806-S (ISGLOBAL); and cofinancing with funds from the European Regional Development Fund by the Spanish Ministry of Science and Innovation corresponding to the Programa Operativo FEDER Plurirregional de España (POPE) 2014 to 2020 and by the Secretaria d’Universitats i Recerca, Departament d’Empresa i Coneixement of the Generalitat de Catalunya corresponding to the Programa Operatiu FEDER de Catalunya 2014 to 2020.
Repisalud
Publication Artículo científico (JournalArticle)

Improved Diagnosis of Rare Disease Patients through Systematic Detection of Runs of Homozygosity

  • Matalonga, Leslie
  • Laurie, Steven
  • Papakonstantinou, Anastasios
  • Piscia, Davide
  • Mereu, Elisabetta
  • Bullich, Gemma
  • Thompson, Rachel
  • Horvath, Rita
  • Pérez-Jurado, Luis Alberto
  • Riess, Olaf
  • Gut, Ivo
  • van Ommen, Gert-Jan
  • Lochmüller, Hanns
  • Beltran, Sergi
  • RD–Connect Genome-Phenome Analysis Platform
  • URD-Cat Data Contributors
  • Posada De la Paz, Manuel
Autozygosity is associated with an increased risk of genetic rare disease, thus being a relevant factor for clinical genetic studies. More than 2400 exome sequencing data sets were analyzed and screened for autozygosity on the basis of detection of >1 Mbp runs of homozygosity (ROHs). A model was built to predict if an individual is likely to be a consanguineous offspring (accuracy, 98%), and probability of consanguinity ranges were established according to the total ROH size. Application of the model resulted in the reclassification of the consanguinity status of 12% of the patients. The analysis of a subset of 79 consanguineous cases with the Rare Disease (RD)-Connect Genome-Phenome Analysis Platform, combining variant filtering and homozygosity mapping, enabled a 50% reduction in the number of candidate variants and the identification of homozygous pathogenic variants in 41 patients, with an overall diagnostic yield of 52%. The newly defined consanguinity ranges provide, for the first time, specific ROH thresholds to estimate inbreeding within a pedigree on disparate exome sequencing data, enabling confirmation or (re)classification of consanguineous status, hence increasing the efficiency of molecular diagnosis and reporting on secondary consanguinity findings, as recommended by American College of Medical Genetics and Genomics guidelines.
Repisalud
Publication Artículo científico (JournalArticle)

The RD-Connect Genome-Phenome Analysis Platform: Accelerating diagnosis, research, and gene discovery for rare diseases

  • Laurie, Steven
  • Piscia, Davide
  • Matalonga, Leslie
  • Corvó, Alberto
  • Fernández-Callejo, Marcos
  • Garcia-Linares, Carles
  • Hernández-Ferrer, Carles
  • Luengo, Cristina
  • Martínez, Inés
  • Papakonstantinou, Anastasios
  • Picó-Amador, Daniel
  • Protasio, Joan
  • Thompson, Rachel
  • Tonda, Raul
  • Bayés, Mònica
  • Bullich, Gemma
  • Camps-Puchadas, Jordi
  • Paramonov, Ida
  • Trotta, Jean-Rémi
  • Alonso, Angel
  • Attimonelli, Marcella
  • Béroud, Christophe
  • Bros-Facer, Virginie
  • Buske, Orion J
  • Cañada-Pallarés, Andrés
  • Fernández, José M
  • Hansson, Mats G
  • Horvath, Rita
  • Jacobsen, Julius O B
  • Kaliyaperumal, Rajaram
  • Lair-Préterre, Séverine
  • Licata, Luana
  • Lopes, Pedro
  • Lopez-Martin, Estrella
  • Mascalzoni, Deborah
  • Monaco, Lucia
  • Pérez-Jurado, Luis Alberto
  • Posada De la Paz, Manuel
  • Rambla, Jordi
  • Rath, Ana
  • Riess, Olaf
  • Robinson, Peter N
  • Salgado, David
  • Smedley, Damian
  • Spalding, Dylan
  • 't Hoen, Peter A C
  • Töpf, Ana
  • Zaharieva, Irina
  • Graessner, Holm
  • Gut, Ivo G
  • Lochmüller, Hanns
  • Beltran, Sergi
Rare disease patients are more likely to receive a rapid molecular diagnosis nowadays thanks to the wide adoption of next-generation sequencing. However, many cases remain undiagnosed even after exome or genome analysis, because the methods used missed the molecular cause in a known gene, or a novel causative gene could not be identified and/or confirmed. To address these challenges, the RD-Connect Genome-Phenome Analysis Platform (GPAP) facilitates the collation, discovery, sharing, and analysis of standardized genome-phenome data within a collaborative environment. Authorized clinicians and researchers submit pseudonymised phenotypic profiles encoded using the Human Phenotype Ontology, and raw genomic data which is processed through a standardized pipeline. After an optional embargo period, the data are shared with other platform users, with the objective that similar cases in the system and queries from peers may help diagnose the case. Additionally, the platform enables bidirectional discovery of similar cases in other databases from the Matchmaker Exchange network. To facilitate genome-phenome analysis and interpretation by clinical researchers, the RD-Connect GPAP provides a powerful user-friendly interface and leverages tens of information sources. As a result, the resource has already helped diagnose hundreds of rare disease patients and discover new disease causing genes.
Repisalud
Publication Artículo científico (JournalArticle)

Solving patients with rare diseases through programmatic reanalysis of genome-phenome data

  • Matalonga, Leslie
  • Hernández-Ferrer, Carles
  • Piscia, Davide
  • Schüle, Rebecca
  • Synofzik, Matthis
  • Töpf, Ana
  • Vissers, Lisenka E L M
  • de Voer, Richarda
  • Tonda, Raul
  • Laurie, Steven
  • Fernández-Callejo, Marcos
  • Picó, Daniel
  • Garcia-Linares, Carles
  • Papakonstantinou, Anastasios
  • Corvó, Alberto
  • Joshi, Ricky
  • Diez, Hector
  • Gut, Ivo
  • Hoischen, Alexander
  • Graessner, Holm
  • Beltran, Sergi
  • Solve-RD Consortia
  • Cuesta de la Plaza, Isabel
  • Lopez-Martin, Estrella
  • Posada De la Paz, Manuel
  • Bermejo-Sanchez, Eva
  • Martinez-Delgado, Beatriz
  • Alonso, Javier
Reanalysis of inconclusive exome/genome sequencing data increases the diagnosis yield of patients with rare diseases. However, the cost and efforts required for reanalysis prevent its routine implementation in research and clinical environments. The Solve-RD project aims to reveal the molecular causes underlying undiagnosed rare diseases. One of the goals is to implement innovative approaches to reanalyse the exomes and genomes from thousands of well-studied undiagnosed cases. The raw genomic data is submitted to Solve-RD through the RD-Connect Genome-Phenome Analysis Platform (GPAP) together with standardised phenotypic and pedigree data. We have developed a programmatic workflow to reanalyse genome-phenome data. It uses the RD-Connect GPAP's Application Programming Interface (API) and relies on the big-data technologies upon which the system is built. We have applied the workflow to prioritise rare known pathogenic variants from 4411 undiagnosed cases. The queries returned an average of 1.45 variants per case, which first were evaluated in bulk by a panel of disease experts and afterwards specifically by the submitter of each case. A total of 120 index cases (21.2% of prioritised cases, 2.7% of all exome/genome-negative samples) have already been solved, with others being under investigation. The implementation of solutions as the one described here provide the technical framework to enable periodic case-level data re-evaluation in clinical settings, as recommended by the American College of Medical Genetics.
Repisalud
Publication Artículo científico (JournalArticle)

A Solve-RD ClinVar-based reanalysis of 1522 index cases from ERN-ITHACA reveals common pitfalls and misinterpretations in exome sequencing

  • Denommé-Pichon, Anne-Sophie
  • Matalonga, Leslie
  • de Boer, Elke
  • Jackson, Adam
  • Benetti, Elisa
  • Banka, Siddharth
  • Bruel, Ange-Line
  • Ciolfi, Andrea
  • Clayton-Smith, Jill
  • Dallapiccola, Bruno
  • Duffourd, Yannis
  • Ellwanger, Kornelia
  • Fallerini, Chiara
  • Gilissen, Christian
  • Graessner, Holm
  • Haack, Tobias B
  • Havlovicova, Marketa
  • Hoischen, Alexander
  • Jean-Marçais, Nolwenn
  • Kleefstra, Tjitske
  • Lopez-Martin, Estrella
  • Macek, Milan
  • Mencarelli, Maria Antonietta
  • Moutton, Sébastien
  • Pfundt, Rolph
  • Pizzi, Simone
  • Posada De la Paz, Manuel
  • Radio, Francesca Clementina
  • Renieri, Alessandra
  • Rooryck, Caroline
  • Ryba, Lukas
  • Safraou, Hana
  • Schwarz, Martin
  • Tartaglia, Marco
  • Thauvin-Robinet, Christel
  • Thevenon, Julien
  • Tran Mau-Them, Frederic
  • Trimouille, Aurélien
  • Votypka, Pavel
  • de Vries, Bert B A
  • Willemsen, Marjolein H
  • Zurek, Birte
  • Verloes, Alain
  • Philippe, Christophe
  • Vitobello, Antonio
  • Vissers, Lisenka E L M
  • Faivre, Laurence
Purpose: Within the Solve-RD project (https://solve-rd.eu/), the European Reference Network for Intellectual disability, TeleHealth, Autism and Congenital Anomalies aimed to investigate whether a reanalysis of exomes from unsolved cases based on ClinVar annotations could establish additional diagnoses. We present the results of the "ClinVar low-hanging fruit" reanalysis, reasons for the failure of previous analyses, and lessons learned. Methods: Data from the first 3576 exomes (1522 probands and 2054 relatives) collected from European Reference Network for Intellectual disability, TeleHealth, Autism and Congenital Anomalies was reanalyzed by the Solve-RD consortium by evaluating for the presence of single-nucleotide variant, and small insertions and deletions already reported as (likely) pathogenic in ClinVar. Variants were filtered according to frequency, genotype, and mode of inheritance and reinterpreted. Results: We identified causal variants in 59 cases (3.9%), 50 of them also raised by other approaches and 9 leading to new diagnoses, highlighting interpretation challenges: variants in genes not known to be involved in human disease at the time of the first analysis, misleading genotypes, or variants undetected by local pipelines (variants in off-target regions, low quality filters, low allelic balance, or high frequency). Conclusion: The "ClinVar low-hanging fruit" analysis represents an effective, fast, and easy approach to recover causal variants from exome sequencing data, herewith contributing to the reduction of the diagnostic deadlock.
Repisalud
Publication Artículo científico (JournalArticle)

Getting your DUCs in a row - standardising the representation of Digital Use Conditions

  • Jeanson, Francis
  • Gibson, Spencer J
  • Alper, Pinar
  • Bernier, Alexander
  • Woolley, J Patrick
  • Mietchen, Daniel
  • Strug, Andrzej
  • Becker, Regina
  • Kamerling, Pim
  • Sánchez González, María Del Carmen
  • Mah, Nancy
  • Novakowski, Ann
  • Wilkinson, Mark D
  • Benhamed, Oussama Mohammed
  • Landi, Annalisa
  • Krog, Georg Philip
  • Müller, Heimo
  • Riaz, Umar
  • Veal, Colin
  • Holub, Petr
  • van Enckevort, Esther
  • Brookes, Anthony J
Improving patient care and advancing scientific discovery requires responsible sharing of research data, healthcare records, biosamples, and biomedical resources that must also respect applicable use conditions. Defining a standard to structure and manage these use conditions is a complex and challenging task. This is exemplified by a near unlimited range of asset types, a high variability of applicable conditions, and differing applications at the individual or collective level. Furthermore, the specifics and granularity required are likely to vary depending on the ultimate contexts of use. All these factors confound alignment of institutional missions, funding objectives, regulatory and technical requirements to facilitate effective sharing. The presented work highlights the complexity and diversity of the problem, reviews the current state of the art, and emphasises the need for a flexible and adaptable approach. We propose Digital Use Conditions (DUC) as a framework that addresses these needs by leveraging existing standards, striking a balance between expressiveness versus ambiguity, and considering the breadth of applicable information with their context of use.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publication Artículo científico (JournalArticle)

NOTCH3 Variant Position Affects the Phenotype at the Pluripotent Stem Cell Level in CADASIL

  • Bugallo Casal, Ana
  • Castillo Sánchez, José Antonio
  • Campos, Francisco
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common genetic form of stroke. It is caused by a cysteine-altering variant in one of the 34 epidermal growth factor-like repeat (EGFr) domains of Notch3. NOTCH3 pathogenic variants in EGFr 1–6 are associated with high disease severity, whereas those in EGFr 7–34 are associated with late stroke onset and increased survival. However, whether and how the position of the NOTCH3 variant directly affects the disease severity remains unclear. In this study, we aimed to generate human-induced pluripotent stem cells (hiPSCs) from patients with CADASIL with EGFr 1–6 and 7–34 pathogenic variants to evaluate whether the NOTCH3 position affects the cell phenotype and protein profile of the generated hiPSCs lines. Six hiPSCs lines were generated: two from patients with CADASIL with EGFr 1–6 pathogenic variants, two from patients with EGFr 7–34 variants, and two from controls. Notch3 aggregation and protein profiles were tested in the established six hiPSCs lines. Cell analysis revealed that the NOTCH3 variants did not limit the cell reprogramming efficiency. However, EGFr 1–6 variant position was associated with increased accumulation of Notch3 protein in pluripotent stem cells and proteomic changes related with cytoplasmic reorganization mechanisms. In conclusion, our analysis of hiPSCs derived from patients with CADASIL support the clinical association between the NOTCH3 variant position and severity of CADASIL.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

The RD-connect genome-phenome analysis platform: accelerating diagnosis, research, and gene discovery for rare diseases

  • Laurie, Steven
  • Piscia, Davide
  • Matalonga, Leslie
  • Corvó, Alberto
  • Fernández-Callejo, Marcos
  • Garcia-Linares, Carles
  • Hernandez-Ferrer, Carles
  • Luengo, Cristina
  • Martínez, Inés
  • Papakonstantinou, Anastasios
  • Picó-Amador, Daniel
  • Protasio, Joan
  • Thompson, Rachel
  • Tonda, Raúl
  • Bayés, Mónica
  • Bullich, Gemma
  • Camps-Puchadas, Jordi
  • Paramonov, Ida
  • Trotta, Jean Remí
  • Alonso Sánchez, Ángel Miguel
  • Attimonelli, Marcella
  • Béroud, Christophe
  • Bros-Facer, Virginie
  • Buske, Orion J.
  • Cañada-Pallarés, Andrés
  • Fernández, José M.
  • Hansson, Mats G.
  • Horvath, Rita
  • Jacobsen, Julius O. B.
  • Kaliyaperumal, Rajaram
  • Lair-Préterre, Séverine
  • Licata, Luana
  • Lopes, Pedro
  • López-Martín, Estrella
  • Mascalzoni, Deborah
  • Monaco, Lucia
  • Pérez-Jurado, Luis A.
  • Posada-de-la-Paz, Manuel
  • Rambla, Jordi
  • Rath, Ana
  • Riess, Olaf
  • Robinson, Peter N.
  • Salgado, David
  • Smedley, Damian
  • Spalding, Dylan
  • 't Hoen, Peter A. C.
  • Töpf, Ana
  • Zaharieva, Irina
  • Graessner, Holm
  • Gut, Ivo Glynne
  • Lochmüller, Hanns
  • Beltrán, Sergi
Rare disease patients are more likely to receive a rapid molecular diagnosis nowadays thanks to the wide adoption of next-generation sequencing. However, many cases remain undiagnosed even after exome or genome analysis, because the methods used missed the molecular cause in a known gene, or a novel causative gene could not be identified and/or confirmed. To address these challenges, the RD-Connect Genome-Phenome Analysis Platform (GPAP) facilitates the collation, discovery, sharing, and analysis of standardized genome-phenome data within a collaborative environment. Authorized clinicians and researchers submit pseudonymised phenotypic profiles encoded using the Human Phenotype Ontology, and raw genomic data which is processed through a standardized pipeline. After an optional embargo period, the data are shared with other platform users, with the objective that similar cases in the system and queries from peers may help diagnose the case. Additionally, the platform enables bidirectional discovery of similar cases in other databases from the Matchmaker Exchange network. To facilitate genome-phenome analysis and interpretation by clinical researchers, the RD-Connect GPAP provides a powerful user-friendly interface and leverages tens of information sources. As a result, the resource has already helped diagnose hundreds of rare disease patients and discover new disease causing genes., RD-Connect (RD-Connect, an integrated platform connecting registries, biobanks, and clinical bioinformatics) received funding from the Seventh Framework (FP7) Programme of the European Union under grant agreement No 305444. Data were analyzed using the RD-Connect GPAP, which received funding from EU projects Solve-RD, EJP-RD (grant numbers H2020 779257, H2020 825575), Instituto de Salud Carlos III (Grant numbers PT13/0001/0044, PT17/0009/0019; Instituto Nacional de Bioinformática, INB), ELIXIR-EXCELERATE (Grant number EU H2020 #676559) and ELIXIR Implementation Studies (Remote real-time visualization of human rare disease genomics data (RD-Connect) stored at the EGA ELIXIR. 2017-2018; ELIXIR IT-2017-INTEGRATION, Rare Disease Infrastructure ELIXIR, 2019-2020 and the Beacon ELIXIR, 2019-2021). The RD-Connect GPAP has leveraged developments funded through project VEIS (001-P-001647 co-financed by the European Regional Development Fund of the European Union in the framework of the Operational Program FEDER of Catalonia 2014-2020 with the support of the Secretaria d'Universitats i Recerca del Departament d'Empresa i Coneixement de la Generalitat de Catalunya) and URD-Cat (PERIS SLT002/16/00174, Departament de Salut, Generalitat de Catalunya). The research leading to these results has received funding from Consequitur (Newton Fund UK/Turkey, MR/N027302/1), BBMRI-LPC (EU FP7 #313010), NeurOmics (EU FP7 #305121), the Economic Development Department of the Navarra Government (Grant number 001114112017), the European Reference Network for Rare Neurological Diseases (Project ID number 739510) and NIH, National Institute of Child Health and Human Development (1R01HD103805-01). We acknowledge the support of the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Program/Generalitat de Catalunya. We also acknowledge the support of the Generalitat de Catalunya through Departament de Salut and Departament d'Empresa i Coneixement and Co-financing by the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) with funds from the European Regional Development Fund (ERDF) corresponding to the 2014-2020 Smart Growth Operating Program. HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279).
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Improved diagnosis of rare disease patients through systematic detection of runs of homozygosity

  • Matalonga Borrel, Lesley
  • Laurie, Steven
  • Papakonstantinou, Anastasios
  • Piscia, Davide
  • Mereu, Elisabetta
  • Bullich, Gemma
  • Thompson, Rachel
  • Horvath, Rita
  • Pérez Jurado, Luis A.
  • Riess, Olaf
  • Gut, Ivo
  • van Ommen, Gert Jan
  • Lochmüller, Hanns
  • Beltrán, Sergi
  • Rare Disease-Connect Genome-Phenome Analysis Platform data contributors
  • Undiagnosed Rare Disease Programme of Catalonia data contibutors
  • Cormand Rifà, Bru
  • Balcells Comas, Susana
  • Grinberg Vaisman, Daniel Raúl
  • Urreizti, Roser
  • Garrabou Tornos, Glòria
Autozygosity is associated with an increased risk of genetic rare disease, thus being a relevant factor for clinical genetic studies. More than 2400 exome sequencing data sets were analyzed and screened for autozygosity on the basis of detection of >1 Mbp runs of homozygosity (ROHs). A model was built to predict if an individual is likely to be a consanguineous offspring (accuracy, 98%), and probability of consanguinity ranges were established according to the total ROH size. Application of the model resulted in the reclassification of the consanguinity status of 12% of the patients. The analysis of a subset of 79 consanguineous cases with the Rare Disease (RD)-Connect Genome-Phenome Analysis Platform, combining variant filtering and homozygosity mapping, enabled a 50% reduction in the number of candidate variants and the identification of homozygous pathogenic variants in 41 patients, with an overall diagnostic yield of 52%. The newly defined consanguinity ranges provide, for the first time, specific ROH thresholds to estimate inbreeding within a pedigree on disparate exome sequencing data, enabling confirmation or (re)classification of consanguineous status, hence increasing the efficiency of molecular diagnosis and reporting on secondary consanguinity findings, as recommended by American College of Medical Genetics and Genomics guidelines
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

The 'A' of FAIR - As Open as Possible, as Closed as Necessary

  • Landi, Annalisa
  • Thompson, Mark
  • Giannuzzi, Viviana
  • Bonifazi, Fedele
  • Labastida i Juan, Ignasi, 1970-
  • Bonino da Silva Santos, Luiz Olavo
  • Roos, Marco
In order to provide responsible access to health data by reconciling benefits of data sharing with privacy rights and ethical and regulatory requirements, Findable, Accessible, Interoperable and Reusable (FAIR) metadata should be developed. According to the H2020 Program Guidelines on FAIR Data, data should be 'as open as possible and as closed as necessary', 'open' in order to foster the reusability and to accelerate research, but at the same time they should be 'closed' to safeguard the privacy of the subjects. Additional provisions on the protection of natural persons with regard to the processing of personal data have been endorsed by the European General Data Protection Regulation (GDPR), Reg (EU) 2016/679, that came into force in May 2018. This work aims to solve accessibility problems related to the protection of personal data in the digital era and to achieve a responsible access to and responsible use of health data. We strongly suggest associating each data set with FAIR metadata describing both the type of data collected and the In order to provide responsible access to health data by reconciling benefits of data sharing with privacy rights and ethical and regulatory requirements, Findable, Accessible, Interoperable and Reusable (FAIR) metadata should be developed. According to the H2020 Program Guidelines on FAIR Data, data should be 'as open as possible and as closed as necessary', 'open' in order to foster the reusability and to accelerate research, but at the same time they should be 'closed' to safeguard the privacy of the subjects. Additional provisions on the protection of natural persons with regard to the processing of personal data have been endorsed by the European General Data Protection Regulation (GDPR), Reg (EU) 2016/679, that came into force in May 2018. This work aims to solve accessibility problems related to the protection of personal data in the digital era and to achieve a responsible access to and responsible use of health data. We strongly suggest associating each data set with FAIR metadata describing both the type of data collected and the accessibility conditions by considering data protection obligations and ethical and regulatory requirements. Finally, an existing FAIR infrastructure component has been used as an example to explain how FAIR metadatacould facilitate data sharing while ensuring protection of individuals.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

FAIR Principles: Interpretations and Implementation Considerations

  • Jacobsen, Annika
  • Miranda Azevedo, Ricardo de
  • Juty, Nick
  • Batista, Dominique
  • Coles, Simon J.
  • Cornet, Ronald
  • Courtot, Mélanie
  • Crosas, Mercè
  • Dumontier, Michel
  • Evelo Chris, T.
  • Goble, Carole
  • Guizzardi, Giancarlo
  • Kryger-Hansen, Karsten
  • Hasnain, Ali
  • Hettne, Kristina
  • Heringa, Jaap
  • Hooft, Rob W. W.
  • Imming, Melanie
  • Jeffery, Keith G.
  • Kaliyaperumal, Rajaram
  • Kersloot, Martijn G.
  • Kirkpatrick, Christine R.
  • Kuhn, Tobias
  • Labastida i Juan, Ignasi, 1970-
  • Magagna, Barbara
  • McQuilton, Peter
  • Meyers, Natalie
  • Montesanti, Annalisa
  • van-Reisen, Mirjam
  • Rocca-Serra, Philippe
  • Pergl, Robert
  • Sansone, Susanna-Assunta
  • Bonino da Silva Santos, Luiz Olavo
  • Schneider, Juliane
  • Strawn, George
  • Thompson, Mark
  • Waagmeester, Andra
  • Weigel, Tobias
  • Wilkinson, Mark D.
  • Willighagen, Egon
The FAIR principles have been widely cited, endorsed and adopted by a broad range of stakeholders since their publication in 2016. By intention, the 15 FAIR guiding principles do not dictate specific technological implementations, but provide guidance for improving Findability, Accessibility, Interoperability and Reusability of digital resources. This has likely contributed to the broad adoption of the FAIR principles, because individual stakeholder communities can implement their own FAIR solutions. However, it has also resulted in inconsistent interpretations that carry the risk of leading to incompatible implementations. Thus, while the FAIR principles are formulated on a high level and may be interpreted and implemented in different ways, for true interoperability we need to support convergence in implementation choices that are widely accessible and (re)-usable. We introduce the concept of FAIR implementation considerations to assist accelerated global participation and convergence towards accessible, robust, widespread and consistent FAIR implementations. Any self-identified stakeholder community may either choose to reuse solutions from existing implementations, or when they spot a gap, accept the challenge to create the needed solution, which, ideally, can be used again by other communities in the future. Here, we provide interpretations and implementation considerations (choices and challenges) for each FAIR principle.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Beacon v2 and Beacon networks: A “lingua franca” for federated data discovery in biomedical genomics, and beyond

  • Rambla, Jordi
  • Baudis, Michael
  • Ariosa, Roberto
  • Beck, Tim
  • Fromont, Lauren A.
  • Navarro, Arcadi
  • Paloots, Rahel
  • Rueda, Manuel
  • Saunders, Gary
  • Singh, Babita
  • Spalding, John D.
  • Törnroos, Juha
  • Vasallo, Claudia
  • Veal, Colin D.
  • Brookes, Anthony J.
Beacon is a basic data discovery protocol issued by the Global Alliance for Genomics and Health (GA4GH). The main goal addressed by version 1 of the Beacon protocol was to test the feasibility of broadly sharing human genomic data, through providing simple “yes” or “no” responses to queries about the presence of a given variant in datasets hosted by Beacon providers. The popularity of this concept has fostered the design of a version 2, that better serves real-world requirements and addresses the needs of clinical genomics research and healthcare, as assessed by several contributing projects and organizations. Particularly, rare disease genetics and cancer research will benefit from new case level and genomic variant level requests and the enabling of richer phenotype and clinical queries as well as support for fuzzy searches. Beacon is designed as a “lingua franca” to bridge data collections hosted in software solutions with different and rich interfaces. Beacon version 2 works alongside popular standards like Phenopackets, OMOP, or FHIR, allowing implementing consortia to return matches in beacon responses and provide a handover to their preferred data exchange format. The protocol is being explored by other research domains and is being tested in several international projects., This study was funded by ELIXIR, the research infrastructure for life-science data and also by LaCaixa Foundation (grant number 004745/008034). Tim Beck was supported by a UKRI Innovation Fellowship at Health Data Research UK (MR/S003703/1). Anthony J. Brookes and Jordi Rambla were supported, in part, by the European Union's Horizon 2020 research and innovation program under the EJP RD COFUND-EJP #825575. Michael Baudis acknowledges funding under the BioMedIT Network project of Swiss Institute of Bioinformatics (SIB) and Swiss Personalized Health Network (SPHN)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Alexander disease– the road ahead

  • Pajares, María Ángeles
  • Hernández-Gerez, Elena
  • Pekny, Milos
  • Pérez-Sala, Dolores
13 p.-2 fig., Alexander disease is a rare neurodegenerative disorder caused by mutations in the glial fibrillary acidic protein, a type III intermediate filament protein expressed in astrocytes. Both early (infantile or juvenile) and adult onsets of the disease are known and, in both cases, astrocytes present characteristic aggregates, named Rosenthal fibers. Mutations are spread along the glial fibrillary acidic protein sequence disrupting the typical filament network in a dominant manner. Although the presence of aggregates suggests a proteostasis problem of the mutant forms, this behavior is also observed when the expression of wild-type glial fibrillary acidic protein is increased. Additionally, several isoforms of glial fibrillary acidic protein have been described to date, while the impact of the mutations on their expression and proportion has not been exhaustively studied. Moreover, the posttranslational modification patterns and/or the protein-protein interaction networks of the glial fibrillary acidic protein mutants may be altered, leading to functional changes that may modify the morphology, positioning, and/or the function of several organelles, in turn, impairing astrocyte normal function and subsequently affecting neurons. In particular, mitochondrial function, redox balance and susceptibility to oxidative stress may contribute to the derangement of glial fibrillary acidic protein mutant-expressing astrocytes. To study the disease and to develop putative therapeutic strategies, several experimental models have been developed, a collection that is in constant growth. The fact that most cases of Alexander disease can be related to glial fibrillary acidic protein mutations, together with the availability of new and more relevant experimental models, holds promise for the design and assay of novel therapeutic strategies., Work at the authors’ laboratories is supported by grants from “la Caixa” Foundation, Grant Agreement LCF/PR/HR21/52410002 and EJP RD COFUND-EJP N° 825575 “Alexander” to DPS and MP; Agencia Estatal de Investigación, MICINN and ERDF Grant No. RTI2018-097624-B-I00 and PID2021-126827OB-I00 to DPS, and grants from the Swedish Research Council (2017-02255), ALF Gothenburg (146051), The Swedish Society for Medical Research, Hjärnfonden, Söderberg’s Foundations, Hagströmer’s Foundation Millennium, Amlöv’s Foundation, E. Jacobson’s Donation Fund, and the Swedish Stroke Foundation, NanoNet COST Action (BM1002), and EU FP 7 Program TargetBraIn (279017) to MP., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Appraising the role of astrocytes as suppliers of neuronal glutathione precursors

  • Pérez-Sala, Dolores
  • Pajares, María Ángeles
The metabolism and intercellular transfer of glutathione or its precursors may play an important role in cellular defense against oxidative stress, a common hallmark of neurodegeneration. In the 1990s, several studies in the Neurobiology field led to the widely accepted notion that astrocytes produce large amounts of glutathione that serve to feed neurons with precursors for glutathione synthesis. This assumption has important implications for health and disease since a reduction in this supply from astrocytes could compromise the capacity of neurons to cope with oxidative stress. However, at first glance, this shuttling would imply a large energy expenditure to get to the same point in a nearby cell. Thus, are there additional underlying reasons for this expensive mechanism? Are neurons unable to import and/or synthesize the three non-essential amino acids that are the glutathione building blocks? The rather oxidizing extracellular environment favors the presence of cysteine (Cys) as cystine (Cis), less favorable for neuronal import. Therefore, it has also been proposed that astrocytic GSH efflux could induce a change in the redox status of the extracellular space nearby the neurons, locally lowering the Cis/Cys ratio. This astrocytic glutathione release would also increase their demand for precursors, stimulating Cis uptake, which these cells can import, further impacting the local decline of the Cis/Cys ratio, in turn, contributing to a more reduced extracellular environment and subsequently favoring neuronal Cys import. Here, we revisit the experimental evidence that led to the accepted hypothesis of astrocytes acting as suppliers of neuronal glutathione precursors, considering recent data from the Human Protein Atlas. In addition, we highlight some potential drawbacks of this hypothesis, mainly supported by heterogeneous cellular models. Finally, we outline additional and more cost-efficient possibilities by which astrocytes could support neuronal glutathione levels, including its shuttling in extracellular vesicles., This work was supported by “la Caixa” Foundation, Grant Agreement LCF/PR/HR21/52410002, the European Union Horizon H2020 EJP RD COFUND-EJP Nº 825575 “Alexander”, grants Nº RTI2018-097624-B-I00 and PID2021-126827OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe” to D.P.S., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

FAIR Data Point: A FAIR-Oriented Approach for Metadata Publication

  • da Silva Santos, Luiz Olavo Bonino
  • Burger, Kees
  • Kaliyaperumal, Rajaram
  • Wilkinson, Mark D.
21 Pág., Metadata, data about other digital objects, play an important role in FAIR with a direct relation to all FAIR principles. In this paper we present and discuss the FAIR Data Point (FDP), a software architecture aiming to define a common approach to publish semantically-rich and machine-actionable metadata according to the FAIR principles. We present the core components and features of the FDP, its approach to metadata provision, the criteria to evaluate whether an application adheres to the FDP specifications and the service to register, index and allow users to search for metadata content of available FDPs., Currently, LOBSS, RK and KB are partially funded from the EU's Horizon 2020 project FAIRsFAIR (grant number 831558). MDW and RK are funded via the EU's Horizon 2020 research and innovation programme under the EJP RD COFUND-EJP #825575., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The FAIR Data Point: Interfaces and Tooling

  • Mohammed Benhamed, Oussama
  • Burger, Kees
  • Kaliyaperumal, Rajaram
  • Santos, Luiz Olavo Bonino da Silva
  • Suchánek, Marek
  • Slifka, Jan
  • Wilkinson, Mark D.
18 Pág., While the FAIR Principles do not specify a technical solution for ‘FAIRness’, it was clear from the outset of the FAIR initiative that it would be useful to have commodity software and tooling that would simplify the creation of FAIR-compliant resources. The FAIR Data Point is a metadata repository that follows the DCAT(2) schema, and utilizes the Linked Data Platform to manage the hierarchical metadata layers as LDP Containers. There has been a recent flurry of development activity around the FAIR Data Point that has significantly improved its power and ease-of-use. Here we describe five specific tools—an installer, a loader, two Web-based interfaces, and an indexer—aimed at maximizing the uptake and utility of the FAIR Data Point., OMB is funded by a fellowship from the Algerian Ministry of Higher Education and Scientific Research. MDW and RK are funded via the European Union's Horizon 2020 research and innovation programme under the EJP RD COFUND-EJP No. 825575. The research activities of MS and JS are supported by Czech Technical University in Prague grant No. SGS20/209/OHK3/3T/18. LOBSS, RK and KB are partially funded by funding from the Horizon2020 projects FAIRsFAIR grant No. 831558., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A Resource for Guiding Data Stewards to Make European Rare Disease Patient Registries FAIR

  • van Damme, Philip
  • Alarcón-Moreno, Pablo
  • Bernabé, César Henrique
  • Cámara, Alberto
  • Le Cornec, Clémence M. A.
  • Dos Santos Vieira, Bruna
  • Van der Velde, K. Joeri
  • Zhang, Shuxin
  • Carta, Claudio
  • Cornet, Ronald
  • Hoen, Peter A. C.
  • Jacobsen, Annika
  • Swertz, Morris A.
  • Roos, Marco
  • Benis, Nirupama
12 Pág., Objective: This paper reports on the development of a dynamic data management planning questionnaire to guide data stewards of the European Reference Network (ERN) rare disease patient registries to make their data findable, accessible, interoperable, and reusable (FAIR). As part of this work, the questionnaire was validated through expert review and aligned with existing resources on rare diseases and FAIR data management. Materials and Methods: The questionnaire was developed for the Data Stewardship Wizard, a tool for data management planning. Knowledge sources on FAIR data, ERN patient registries, and data management were used to compose questions. Ten domain experts validated the questionnaire. The topics in the questionnaire were aligned with existing knowledge bases. Results: A total of 57 questions were included in the questionnaire. Twenty-three references to the FAIR Cookbook and Research Data Management toolkit for Life Sciences were added. Expert validation provided a total of 166 comments on content, structure, and software-related issues. A public instance of the Data Stewardship Wizard was deployed for use by data stewards of ERN patient registries. Discussion: The questionnaire addresses issues that ERNs encounter when making their registries FAIR and follows the implementation choices made by the European rare disease community. A challenging task for future research is to extend the questionnaire to other types of registries and to validate with users. Conclusion: This smart questionnaire is the first model created for the Data Stewardship Wizard that helps ERN patient registries with making their data FAIR. It will assist data stewards in aligning their efforts and providing guidance on FAIR data., This work was supported by the EU’s Horizon 2020 research and innovation program under the EJP RD COFUND-EJP No., 825575, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Fair principles: Interpretations and implementation considerations

  • Jacobsen, Annika
  • De Miranda Azevedo, Ricardo
  • Juty, Nick
  • Batista, Dominique
  • Coles, Simon
  • Cornet, Ronald
  • Courtot, Mélanie
  • Crosas, Mercè
  • Dumontier, Michel
  • Evelo, Chris T. A.
  • Goble, Carole
  • Guizzardi, Giancarlo
  • Hansen, Karsten
  • Hasnain, Ali
  • Hettne, Kristina
  • Heringa, Jaap
  • Hooft, Rob W.W.
  • Imming, Melanie
  • Jeffery, Keith
  • Kaliyaperumal, Rajaram
  • Kersloot, Martijn
  • Kirkpatrick, Christine R.
  • Kuhn, Tobias
  • Labastida, Ignasi
  • Magagna, Barbara
  • McQuilton, Peter
  • Meyers, Natalie
  • Montesanti, Annalisa
  • Van Reisen, Mirjam
  • Rocca-Serra, Philippe
  • Pergl, Robert
  • Sansone, Susanna Assunta
  • Santos, Luiz Olavo Bonino da Silva
  • Schneider, Juliane
  • Strawn, George
  • Thompson, Mark
  • Waagmeester, Andra S.
  • Weigel, Tobias
  • Wilkinson, Mark D.
  • Willighagen, Egon L.
  • Wittenburg, Peter
  • Roos, Marco
  • Mons, Barend
  • Schultes, Erik
The FAIR principles have been widely cited, endorsed and adopted by a broad range of stakeholders since their publication in 2016. By intention, the 15 FAIR guiding principles do not dictate specific technological implementations, but provide guidance for improving Findability, Accessibility, Interoperability and Reusability of digital resources. This has likely contributed to the broad adoption of the FAIR principles, because individual stakeholder communities can implement their own FAIR solutions. However, it has also resulted in inconsistent interpretations that carry the risk of leading to incompatible implementations. Thus, while the FAIR principles are formulated on a high level and may be interpreted and implemented in different ways, for true interoperability we need to support convergence in implementation choices that are widely accessible and (re)-usable. We introduce the concept of FAIR implementation considerations to assist accelerated global participation and convergence towards accessible, robust, widespread and consistent FAIR implementations. Any self-identified stakeholder community may either choose to reuse solutions from existing implementations, or when they spot a gap, accept the challenge to create the needed solution, which, ideally, can be used again by other communities in the future. Here, we provide interpretations and implementation considerations (choices and challenges) for each FAIR principle., The work of A. Jacobsen, C. Evelo, M. Thompson, R. Cornet, R. Kaliyaperuma and M. Roos is supported by funding from the European Union’s Horizon 2020 research and innovation program under the EJP RD COFUND-EJP N° 825575. The work of A. Jacobsen, C. Evelo, C. Goble, M. Thompson, N. Juty, R. Hooft, M. Roos, S-A. Sansone, P. McQuilton, P. Rocca-Serra and D. Batista is supported by funding from ELIXIR EXCELERATE, H2020 grant agreement number 676559. R. Hooft was further funded by NL NWO NRGWI. obrug.2018.009. N. Juty and C. Goble were funded by CORBEL (H2020 grant agreement 654248). N. Juty, C. Goble, S-A. Sansone, P. McQuilton, P. Rocca-Serra and D. Batista were funded by FAIRplus (IMI grant agreement 802750). N. Juty, C. Goble, M. Thompson, M. Roos, S-A. Sansone, P. McQuilton, P. Rocca-Serra and D. Batista were funded by EOSClife H2020-EU (grant agreement number 824087). C. Goble was funded by DMMCore (BBSRC BB/M013189/). M. Thompson, M. Roos received funding from NWO (VWData 400.17.605). S-A. Sansone, P. McQuilton, P. Rocca-Serra and D. Batista have been funded by grants awarded to S-A. Sansone from the UK BBSRC and Research Councils (BB/L024101/1; BB/L005069/1), EU (H2020-EU 634107; H2020-EU 654241, IMI (IMPRiND 116060), NIH Data Common Fund, and from the Wellcome Trust (ISA-InterMine 212930/Z/18/Z; FAIRsharing 208381/A/17/Z). The work of A. Waagmeester has been funded by grant award number GM089820 from the National Institutes of Health. M. Kersloot was funded by the European Regional Development Fund (KVW-00163). The work of N. Meyers was funded by the National Science Foundation (OAC 1839030). The work of M.D. Wilkinson is funded by Isaac Peral/Marie Curie cofund with the Universidad Politécnica de Madrid and the Ministerio de Economía y Competitividad grant number TIN2014-55993-RM. The work of B. Magagna, E. Schultes, L. da Silva Santos and K. Jeffery is funded by the H2020-EU 824068. The work of B. Magagna, E. Schultes and L. da Silva Santos is funded by the GO FAIR ISCO grant of the Dutch Ministry of Science and Culture. The work of G. Guizzardi is supported by the OCEAN Project (FUB). M. Courtot received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 802750. R. Cornet was further funded by FAIR4Health (H2020-EU grant agreement number 824666). K. Jeffery received funding from EPOS-IP H2020-EU agreement 676564 and ENVRIplus H2020-EU agreement 654182., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Community-driven governance of FAIRness assessment: an open issue, an open discussion

  • Wilkinson, Mark D.
  • Sansone, Susanna Assunta
  • Méndez, Eva
  • David, Romain
  • Dennis, Richard
  • Hecker, David
  • Kleemola, Mari
  • Lacagnina, Carlo
  • Nikiforova, Anastasija
  • Castro, Leyla Jael
29 Pág., Although FAIR Research Data Principles are targeted at and implemented by different communities, research disciplines, and research stakeholders (data stewards, curators, etc.), there is no conclusive way to determine the level of FAIRness intended or required to make research artefacts (including, but not limited to, research data) Findable, Accessible, Interoperable, and Reusable. The FAIR Principles cover all types of digital objects, metadata, and infrastructures. However, they focus their narrative on data features that support their reusability. FAIR defines principles, not standards, and therefore they do not propose a mechanism to achieve the behaviours they describe in an attempt to be technology/implementation neutral. Various FAIR assessment metrics and tools have been designed to measure FAIRness. Unfortunately, the same digital objects assessed by different tools often exhibit widely different outcomes because of these independent interpretations of FAIR. This results in confusion among the publishers, the funders, and the users of digital research objects. Moreover, in the absence of a standard and transparent definition of what constitutes FAIR behaviours, there is a temptation to define existing approaches as being FAIR-compliant rather than having FAIR define the expected behaviours. This whitepaper identifies three high-level stakeholder categories -FAIR decision and policymakers, FAIR custodians, and FAIR practitioners - and provides examples outlining specific stakeholders' (hypothetical but anticipated) needs. It also examines possible models for governance based on the existing peer efforts, standardisation bodies, and other ways to acknowledge specifications and potential benefits. This whitepaper can serve as a starting point to foster an open discussion around FAIRness governance and the mechanism(s) that could be used to implement it, to be trusted, broadly representative, appropriately scoped, and sustainable. We invite engagement in this conversation in an open Google Group fair-assessment-governance@googlegroups.com., : MDW acknowledges funds supporting his work, including the EJP RD initiative which has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement N°825575. SAS acknowledges funds that supports her, including FAIRplus (IMI 802750), EOSC-Life (H2020 EU 824087), FAIRsharing (Wellcome 212930), Precision Toxicology (H2020 EU 965406), UKRI DASH grant (MR/V038966/1), BY-COVID (Horizon EU 101046203), AgroServ (Horizon EU 10105 8020), and the ELIXIR Interoperability Platform. EM acknowledges support from the FAIRsFAIR Fostering FAIR Data Practices in Europe (funding number 831558). RD David was supported by the EOSC-Life European program under grant agreement Nº824087. LJC acknowledges support from the project NFDI4DataScience, part of the German National Research Data Infrastructure funded by the Joint Science Conference (GWK) and the German Research Foundation (DFG), funding number NFDI 34/1., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Autosomal Recessive Cerebellar Ataxias in Europe: Frequency, Onset, and Severity in 677 Patients

  • Traschütz, Andreas
  • Adarmes-Gómez, Astrid
  • Anheim, Mathieu
  • Baets, Jonathan
  • Falkenburger, Björn H.
  • Gburek-Augustat, Janina
  • Doss, Sarah
  • Kamm, Christoph
  • Klivenyi, Peter
  • Grobe-Einsler, Marcus
  • Klopstock, Thomas
  • Minnerop, Martina
  • Münchau, Alexander
  • Pane, Chiara
  • Renaud, Mathilde
  • Santorelli, Filippo M.
  • Schöls, Ludger
  • Timmann, Dagmar
  • Vielhaber, Stefan
  • Haack, Tobias B.
  • Warrenburg, Bart van de
  • Zanni, Ginevra
  • Synofzik, Matthis
© 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made., This work was supported by the European Union's Horizon 2020 research and innovation program as part of the innovation project EVIDENCE-RND under the EJP RD COFUND-EJP (825575 to M.S.), as part of Solve-RD (779257 to J.B., M.S., and B.P.v.d.W.), by the DFG under the frame of EJP-RD network PROSPAX (441409627 to M.S. and B.P.v.d.W.), and by the Clinician Scientist program “PRECISE.net” funded by the Else Kröner-Fresenius-Stiftung (to A.T.). The study was further funded by the Federal Ministry of Education and Research, Germany, and through the TreatHSP network (01GM1905 to L.S.). B.P.v.d.W. receives additional research support from ZonMW, NWO, Hersenstichting, Brugling fonds, Gossweiler Foundation, and Radboud university medical center. L.S., T.K., G.Z., B.P.v.d.W., and M.S. are members of the European Reference Network for Rare Neurological Diseases—Project ID 739510. A.T. receives funding from the University of Tübingen, medical faculty, for the Clinician Scientist Program Grant 439-0-0. P.K. receives funding from University of Szeged (Hetényi Géza: 5S330 A202) and Ministry of Innovation and Technology of Hungary, National Research, Development and Innovation Fund (TKP2021-EGA). J.B. was supported by a Senior Clinical Researcher mandate of the Research Fund—Flanders (FWO) under grant agreement number 1805021N and is a member of the μNEURO Research Centre of Excellence of the University of Antwerp. F.M.S. was supported by the Italian Ministry of Health (the EJP-RD network PROSPAX; Ricerca Finalizzata RF-2016-02361610; RF-2019-12370417; Ricerca Corrente, RC 5x1000). Several authors of this publication are members of the European Reference Network for Rare Neuromuscular Diseases (ERN EURO-NMD) and of the European Reference Network for Rare Neurological Diseases (ERN-RND). Open Access funding enabled and organized by Projekt DEAL., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Responsiveness of the Scale for the Assessment and Rating of Ataxia and Natural History in 884 Recessive and Early Onset Ataxia Patients

  • Traschütz, Andreas
  • Adarmes-Gómez, Astrid
  • Anheim, Mathieu
  • Baets, Jonathan
  • Brais, Bernard
  • Gagnon, Cynthia
  • Gburek-Augustat, Janina
  • Doss, Sarah
  • Hanagasi, Hasmet
  • Kamm, Christoph
  • Klivenyi, Peter
  • Klockgether, Thomas
  • Klopstock, Thomas
  • Minnerop, Martina
  • Münchau, Alexander
  • Renaud, Mathilde
  • Santorelli, Filippo M.
  • Schöls, Ludger
  • Thieme, Andreas
  • Vielhaber, Stefan
  • Warrenburg, Bart van de
  • Zanni, Ginevra
  • Hilgers, Ralf-Dieter
  • PREPARE Consortium
  • Synofzik, Matthis
© 2023 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made., [Objective] The Scale for the Assessment and Rating of Ataxia (SARA) is the most widely applied clinical outcome assessment (COA) for genetic ataxias, but presents metrological and regulatory challenges. To facilitate trial planning, we characterize its responsiveness (including subitem-level relations to ataxia severity and patient-focused outcomes) across a large number of ataxias, and provide first natural history data for several of them., [Methods] Subitem-level correlation and distribution-based analysis of 1,637 SARA assessments in 884 patients with autosomal recessive/early onset ataxia (370 with 2–8 longitudinal assessments) were complemented by linear mixed effects modeling to estimate progression and sample sizes., [Results] Although SARA subitem responsiveness varied between ataxia severities, gait/stance showed a robust granular linear scaling across the broadest range (SARA < 25). Responsiveness was diminished by incomplete subscale use at intermediate or upper levels, nontransitions (“static periods”), and fluctuating decreases/increases. All subitems except nose-finger showed moderate-to-strong correlations to activities of daily living, indicating that metric properties—not content validity—limit SARA responsiveness. SARA captured mild-to-moderate progression in many genotypes (eg, SYNE1-ataxia: 0.55 points/yr, ataxia with oculomotor apraxia type 2: 1.14 points/yr, POLG-ataxia: 1.56 points/yr), but no change in others (autosomal recessive spastic ataxia of Charlevoix-Saguenay, COQ8A-ataxia). Whereas sensitivity to change was optimal in mild ataxia (SARA < 10), it substantially deteriorated in advanced ataxia (SARA > 25; 2.7-fold sample size). Use of a novel rank-optimized SARA without subitems finger-chase and nose-finger reduces sample sizes by 20 to 25%., [Interpretation] This study comprehensively characterizes COA properties and annualized changes of the SARA across and within a large number of ataxias. It suggests specific approaches for optimizing its responsiveness that might facilitate regulatory qualification and trial design. ANN NEUROL 2023;94:470–485, This work was supported via the European Union's Horizon 2020 research and innovation program as part of the innovation project EVIDENCE-RND under the EJP RD COFUND-EJP (No. 825575, to R.-D.H. and M.S.), as part of Solve-RD (No. 779257, to J.B., M.S., and B.P.v.d.W.), by the DFG under the framework of EJP-RD network PROSPAX (No. 441409627; M.S., B.P.v.d.W.), and by the Clinician Scientist program PRECISE.net, funded by the Else Kröner-Fresenius-Stiftung (to A.Tr. and M.S.). The study was further funded by the Federal Ministry of Education and Research, Germany, and through the TreatHSP network (01GM1905 to L.S.). B.P.v.d.W. receives additional research support from ZonMW, Hersenstichting, Gossweiler Foundation, and Radboud University Medical Center. L.S., T.Klop., T.Kloc., G.Z., B.P.v.d.W., and M.S. are members of the European Reference Network for Rare Neurological Diseases–Project ID No. 739510. A.Tr. receives funding from the University of Tübingen, medical faculty, for the Clinician Scientist Program Grant #439-0-0. P.K. receives funding from University of Szeged (Hetényi Géza: 5S330 A202) and Ministry of Innovation and Technology of Hungary, National Research, Development and Innovation Fund (TKP2021-EGA). J.B. is supported by a Senior Clinical Researcher mandate of the Research Fund–Flanders (FWO) under grant agreement number 1805021N, and is a member of the μNEURO Research Center of Excellence of the University of Antwerp. F.M.S. is supported in part by the Italian Ministry of Health (EJP-RD network PROSPAX; Ricerca Finalizzata RF-2016-02361610; RF-2019-12370417; Ricerca Corrente RC 5x1000). Several authors of this publication are members of the European Reference Network for Rare Neuromuscular Diseases and of the European Reference Network for Rare Neurological Diseases., We are grateful to S. Reich for her coordinating support as part of the EOA/PREPARE consortium and to T. Heger for monitoring the datasets of the ARCA registry. Open Access funding enabled and organized by Projekt DEAL., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Getting your DUCs in a row - standardising the representation of Digital Use Conditions

  • Jeanson, Francis
  • Gibson, Spencer
  • Alper, Pinar
  • Bernier, Alexander
  • Woolley, J. Patrick
  • Mietchen, Daniel
  • Strug, Andrzej
  • Becker, Regina
  • Kamerling, Pim
  • Sánchez-González, Mariola
  • Mah, Nancy
  • Novakowski, Ann
  • Wilkinson, Mark D.
  • Benhamed, M.
  • Landi, Annalisa
  • Krog, Georg Philip
  • Müller, Heimo
  • Riaz, Umar
  • Veal, Colin
  • Holub, Petr
  • van Enckevort, Esther
  • Brookes, Anthony
10 Pág., Improving patient care and advancing scientific discovery requires responsible sharing of research data, healthcare records, biosamples, and biomedical resources that must also respect applicable use conditions. Defining a standard to structure and manage these use conditions is a complex and challenging task. This is exemplified by a near unlimited range of asset types, a high variability of applicable conditions, and differing applications at the individual or collective level. Furthermore, the specifics and granularity required are likely to vary depending on the ultimate contexts of use. All these factors confound alignment of institutional missions, funding objectives, regulatory and technical requirements to facilitate effective sharing. The presented work highlights the complexity and diversity of the problem, reviews the current state of the art, and emphasises the need for a flexible and adaptable approach. We propose Digital Use Conditions (DUC) as a framework that addresses these needs by leveraging existing standards, striking a balance between expressiveness versus ambiguity, and considering the breadth of applicable information with their context of use., The authors wish to thank Lotte Boormans (ERN eUROGEN) and Nawel Lalout (World Duchenne Organization) for piloting CCE terms along with DUC software. We also thank the developers of the Digital Use Conditions (DUC) structure and members of the IRDiRC ‘Machine Readable Consent and Use Conditions’ Task Force (https://irdirc.org/machine-readable-consent-and-use-conditions/) for providing project oversight and utility testing of CCEs. Finally, we acknowledge and thank the ‘European Joint Programme on Rare Diseases’ for funding this work as part of the EU Horizon 2020 programme, Grant Agreement N°825575, which contributed to the development work, supported publication costs, and resourced the IRDiRC Scientific Secretariat which is hosted at INSERM in Paris, France., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Common conditions of use elements. Atomic concepts for consistent and effective information governance

  • Sanchez Gonzalez, Maria Del Carmen
  • Kamerling, Pim
  • Iermito, Mariapia
  • Casati, Sara
  • Riaz, Umar
  • Veal, Colin
  • Maini, Monika
  • Jeanson, Francis
  • Benhamed, M.
  • van Enckevort, Esther
  • Landi, Annalisa
  • Mimouni, Yanis
  • Le Cornec, Clémence M. A.
  • Coviello, Domenico
  • Franchin, Tiziana
  • Fusco, Francesca
  • Ramírez García, Jose Antonio
  • van der Zanden, Loes
  • Bernier, Alexander
  • Wilkinson, Mark D.
  • Mueller, Heimo
  • Gibson, Spencer
  • Brookes, Anthony
9 Pág., Myriad policy, ethical and legal considerations underpin the sharing of biological resources, implying the need for standardised and yet flexible ways to digitally represent diverse 'use conditions'. We report a core lexicon of terms that are atomic, non-directional 'concepts of use', called Common Conditions of use Elements. This work engaged biobanks and registries relevant to the European Joint Programme for Rare Diseases and aimed to produce a lexicon that would have generalised utility. Seventy-six concepts were initially identified from diverse real-world settings, and via iterative rounds of deliberation and user-testing these were optimised and condensed down to 20 items. To validate utility, support software and training information was provided to biobanks and registries who were asked to create Sharing Policy Profiles. This succeeded and involved adding standardised directionality and scope annotations to the employed terms. The addition of free-text parameters was also explored. The approach is now being adopted by several real-world projects, enabling this standard to evolve progressively into a universal basis for representing and managing conditions of use., The authors wish to thank Lotte Boormans (ERN eUROGEN) and Nawel Lalout (World Duchenne Organization) for piloting CCE terms along with DUC software. We also thank the developers of the Digital Use Conditions (DUC) structure and members of the IRDiRC ‘Machine Readable Consent and Use Conditions’ Task Force (https://irdirc.org/machine-readable-consent-and-use-conditions/) for providing project oversight and utility testing of CCEs. Finally, we acknowledge and thank the ‘European Joint Programme on Rare Diseases’ for funding this work as part of the EU Horizon 2020 programme, Grant Agreement N°825575, which contributed to the development work, supported publication costs, and resourced the IRDiRC Scientific Secretariat which is hosted at INSERM in Paris, France., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Twelve quick tips for deploying a Beacon

  • Fromont, Lauren A.
  • Moldes, Mauricio
  • Baudis, Michael
  • Brookes, Anthony J.
  • Navarro, Arcadi
  • Rambla, Jordi
© 2024 Fromont et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited., This study was funded by ELIXIR, the research infrastructure for life-science data. The project leading to these results has also received funding and grant support from the “LaCaixa” Foundation under the Grant 004745/008034. LAF was supported, in part, by La Marató TV3, and has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101057182. AJB and JR received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 825575. MB acknowledges funding under the BioMedIT Network project of Swiss Institute of Bioinformatics (SIB) and Swiss Personalized Health Network (SPHN)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Privacy-Preserving Linkage of Distributed Pseudonymised Datasets in a Virtual European Rare Disease Platform

  • Hayn, Dieter
  • Sandner, Emanuel
  • Vengadeswaran, Abishaa
  • Tãtaru, Elena Alexandra
  • Wilkinson, Mark D.
  • Hanauer, Marc
  • Kreiner, Karl
  • Schreier, Guenter
5 Pág., Secondary use of data for research purposes is especially important in rare diseases (RD), since, per definition, data are sparse. The European Joint Programme on Rare Diseases (EJP RD) aims at developing an RD infrastructure which supports the secondary use of data. Significant amounts of RD data are a) distributed and b) available only in pseudonymised format. Privacy-Preserving Record Linkage (PPRL) concerns the linking of such distributed datasets without disclosing the participant's identities. We present a concept for linking a PPRL Service to the EJP RD Virtual Platform (VP). Level 1 (resource discovery) connection is provided by running an FDP within the PPRL Service. On Level 2 (data discoverability), the PPRL Service can represent both, an individual and a catalog endpoint. Our solution can count patients in PPRL-supporting resources, count duplicates only once, and count only patients registered to multiple resources. Currently, we are preparing the deployment within the EJP RD VP., This work was supported by the EJP RD (Grant-number 825575)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Systemic delivery of AAV-GCDH ameliorates HLD-induced phenotype in a glutaric aciduria type I mouse model

  • Mateu-Bosch, Anna
  • Segur-Bailach, Eulàlia
  • Muñoz-Moreno, Emma
  • Barallobre, María-José
  • Arbones, Maria L.
  • Gea-Sorlí, Sabrina
  • Tort, Frederic
  • Ribes, Antonia
  • García-Villoria, Judit
  • Fillat, Cristina
Glutaric aciduria type 1 (GA1) is a rare inherited metabolic disorder caused by a deficiency of glutaryl-coenzyme A dehydrogenase (GCDH), with accumulation of neurotoxic metabolites, resulting in a complex movement disorder, irreversible brain damage, and premature death in untreated individuals. While early diagnosis and a lysine restricted diet can extend survival, they do not prevent neurological damage in approximately one-third of treated patients, and more effective therapies are required. Here we report the efficacy of adeno-associated virus 9 (AAV9)-mediated systemic delivery of human GCDH at preventing a high lysine diet (HLD)-induced phenotype in Gcdh−/− mice. Neonatal treatment with AAV-GCDH restores GCDH expression and enzyme activity in liver and striatum. This treatment protects the mice from HLD-aggressive phenotype with all mice surviving this exposure; in stark contrast, a lack of treatment on an HLD triggers very high accumulation of glutaric acid, 3-hydroxyglutaric acid, and glutarylcarnitine in tissues, with about 60% death due to brain accumulation of toxic lysine metabolites. AAV-GCDH significantly ameliorates the striatal neuropathology, minimizing neuronal dysfunction, gliosis, and alterations in myelination. Magnetic resonance imaging findings show protection against striatal injury. Altogether, these results provide preclinical evidence to support AAV-GCDH gene therapy for GA1., This work was developed at the Centro Esther Koplowitz, Barcelona, Spain. A.M.-B. is the recipient of a PIF-Salut predoctoral contract from Generalitat de Catalunya, Spain. This work was supported by grants to CF from the CIVP19A5949-Fundación Ramón Areces, ACCI-CIBERER, and PID2020-119692RB-C22 Spanish Ministerio de Ciencia e Innovación, with partial support from Fundacio La Caixa, the Generalitat de Catalunya SGR21/01169 and from ISCIII RICORS RD21/0017/0012. We also acknowledge all members of the CHARLIE Consortium (www.charlie.science) for their helpful discussions. This project also received support from Instituto de Salud Carlos III (ISCIII) AC20/00088 under the frame of E-Rare-3, the ERA-Net for Research on Rare Diseases, EJPRD (grant nr: 825575). CIBERER is an initiative of the ISCIII. We also acknowledge the support of CERCA Programme/Generalitat de Catalunya. Graphical abstract was created with Biorender.com., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A cost-effective vessel-on-a-chip for high shear stress applications in vascular biology

  • Becher, Clarissa
  • Frauenlob, Martin
  • Selinger, Florian
  • Ertl, Peter
  • Goumans, Marie-José
  • Sánchez-Duffhues, Gonzalo
The data supporting the findings of this study can be obtained from the corresponding authors upon reasonable request., The vascular endothelium is constantly subjected to hemodynamic forces, including tangential shear stress, which are crucial for maintaining vascular homeostasis. Pathological shear stress levels, such as those observed in pulmonary arterial hypertension (PAH) or atherosclerosis, disrupt this balance, driving vascular remodeling and endothelial dysfunction. Current microfluidic platforms for studying these conditions are limited by high costs, excessive reagent requirements, and non-physiological channel geometries. Here we introduce a novel microfluidic chip system, a Nylon Vessel-on-a-Chip (NVoC) which represents a cost-effective and straightforward fabrication platform that eliminates the need for specialized equipment and enables a physiologically relevant round channel geometry. The NVoC was fabricated using Polydimethylsiloxane (PDMS) and nylon threads, with surface activation achieved through polydopamine and collagen-I coating, enabling robust endothelial cell (EC) attachment and long-term culture. Immortalized endothelial colony-forming cells (iECFCs) and human umbilical vein EC (HUVECs) were used to optimize and validate the platform, demonstrating its compatibility with high shear stress conditions (up to 90 dyne/cm2) and various molecular biology techniques, including RT-qPCR, Western blotting, and immunofluorescent staining. With fabrication costs six times lower than commercial alternatives and overall experimental costs reduced threefold, the NVoC offers the ability to expose endothelial cells to physiological and pathological shear stress levels in a reproducible, accessible, and scalable manner. Its versatility and affordability make it a valuable tool for investigating shear stress-related mechanisms in microvascular diseases, particularly PAH, with potential applications in drug discovery and translational research., This research was further supported by the FWO Scientific Research Network (W0014200N). C.B. and M.J.G. are sponsored by the Netherlands Cardiovascular Research Initiative (the Dutch Heart Foundation, Dutch Federation of University Medical Centers, the Netherlands Organization for Health Research and Development, and the Royal Netherlands Academy of Sciences), PHAEDRA-IMPACT (DCVA), and DOLPHIN-GENESIS (CVON). C.B was sponsored by the European Union’s Horizon 2020 research and innovation programme under the EJP RD COFUND-EJP N° 825575. M.J.G. is supported by regenerative medicine crossing borders (REGMED XB). G.S.D. is supported by the grants Ramón y Cajal RYC2021-030886-I, PID2022-141212OA-I00, and CNS2023-145432 from the Spanish Ministry of Science and Innovation, the BHF-DZHK-DHF, 2022/23 award PROMETHEUS (02-001-2022-0123), and the Foundations Eugenio Rodriguez Pascual (FERP-2023-058) and Mutua Madrileña. F.S. was supported by the Austrian Science Fund (FWF) [doi.org/10.55776/COE7]., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The FLAIR-GG federated network of FAIR germplasm data resources

  • Cámara Ballesteros, Alberto
  • Aguayo Jara, Elena
  • Verykaki, Evrykleia Sofia
  • Pastor del Olmo, Germán
  • Moreno Vázquez, Santiago
  • Torres, Elena
  • Wilkinson, Mark D.
A key source of biodiversity preservation is in the ex situ storage of seed in what are known as germplasm banks (GBs). Unfortunately, wild species germplasm bank databases, often maintained by resource-limited botanical gardens, are highly disparate and capture information about their collections in a wide range of underlying data formats, storage platforms, following different standards, and with varying degrees of data accessibility. Thus, it is extremely difficult to build conservation strategies for wild species via integrating data from these GBs. Here, we envisage that the application of the FAIR Principles to wild species and crop wild relatives information, through the creation of a federated network of FAIR GB databases, would greatly facilitate cross-resource discovery and exploration, thus assisting with the design of more efficient conservation strategies for wild species, and bringing more attention to these key data providers., FLAIR-GG: Proyecto TED2021-130788B-I00 financed by MCIN/AEI /10.13039/501100011033 and by the European Union Next Generation EU/ PRTR. The FLAIR-GG computational infrastructure is supported by the “Severo Ochoa Program for Centres of Excellence in R&D 2022–2025” from the Agencia Estatal de Investigación of Spain, awarded to the Center for Plant Biotechnology and Genomics (CBGP UPM-INIA/CSIC). Several of the technologies described in this work are based on discussions in the European Joint Programme on Rare Disease (EJP-RD) funded by European Union’s Horizon 2020 research and innovation programme under grant agreement N°825575., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Epistaxis Prevention, Treatment, and Future Perspectives for Hereditary Hemorrhagic Telangiectasia

  • Ficany, Anthony
  • Álamo, Marta del
  • Bernabeu, Carmelo
  • Shovlin, Claire L.
  • Rossi, Elisa
This article belongs to the Special Issue Hereditary Hemorrhagic Telangiectasia: Recent Advances and Future Challenges—2nd Edition., Hereditary Hemorrhagic Telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome, is a vascular disorder with a global prevalence ranging from 1:5000 to 1:8000. It most commonly manifests through nosebleeds, which can be frequent and severe, exposing patients to major iron losses, anemia, and considerable physical and emotional distress. To date, no drug has received the FDA or EMA approval for preventing or treating HHT associated epistaxis, limiting access to therapies and intensifying the burden on patients and clinicians. Based on peer-reviewed evidence, the Second International HHT Guidelines provided a stepwise approach to help physicians manage HHT-related epistaxis highlighting the role of anti-fibrinolytic and systemic antiangiogenic drugs. However, experience from clinical practice and trials indicates marked variability in patient responses, and none of the recommended approaches has demonstrated sufficient placebo-controlled efficacy to gain regulatory approval. Striking insights in HHT physiopathology shed light on complex dysregulated signaling pathways with a triggering role not only by angiogenesis as widely recognized, but also by inflammation, injury and other stimuli, pointing to novel therapeutic targets. This review outlines current recommendations for preventing and managing nosebleeds in HHT patients, highlights the latest insights into the development of telangiectasic lesions, and discusses potential therapeutic treatments currently under clinical investigation., This research was funded by Université Paris Cité and AMRO Foundation [IDEX grant] to E.R., the European Union’s Horizon 2020 research and innovation program [EJP RD CO-FUND-EJP N° 825575] to M.D.A, and the NIHR Imperial Biomedical Research Centre (BRC) to C.L.S., Peer reviewed
UPCommons. Portal del coneixement obert de la UPC
Publication Artículo científico (JournalArticle)

Overlap of vitamin A and vitamin D target genes with CAKUT-related processes [version 2, peer review: 2 approved, 2 approved with reservations]

  • Ozisik, Ozan
  • Ehrhart, Friederike
  • Evelo, Chris T.
  • Mantovani, Alberto
  • Baudot, Anaı̈s
Congenital Anomalies of the Kidney and Urinary Tract (CAKUT) are a group of abnormalities affecting the kidneys and their outflow tracts. CAKUT patients display a large clinical variability as well as a complex aetiology. Only 5% to 20% of the cases have a monogenic origin. It is thereby suspected that interactions of both genetic and environmental factors contribute to the disease. Vitamins are among the environmental factors that are considered for CAKUT aetiology. In this study, we aimed to investigate whether vitamin A or vitamin D could have a role in CAKUT aetiology. For this purpose we collected vitamin A and vitamin D target genes and computed their overlap with CAKUT-related gene sets. We observed limited overlap between vitamin D targets and CAKUT-related gene sets. We however observed that vitamin A target genes significantly overlap with multiple CAKUT-related gene sets, including CAKUT causal and differentially expressed genes, and genes involved in renal system development. Overall, these results indicate that an excess or deficiency of vitamin A might be relevant to a broad range of urogenital abnormalities., Grant information: This study has been conducted in context of the European Joint Programme on Rare Diseases (EJP RD) which has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N°825575. Ozan Ozisik has received funding from the Excellence Initiative of Aix-Marseille University - A*Midex, a French “Investissements d’Avenir” programme., Peer Reviewed
UPCommons. Portal del coneixement obert de la UPC
Publication Artículo científico (JournalArticle)

System-level analysis of genes mutated in muscular dystrophies reveals a functional pattern associated with muscle weakness distribution

  • Ozisik, Ozan
  • Gorokhova, Svetlana
  • Cerino, Mathieu
  • Bartoli, Marc
  • Baudot, Anaïs
Muscular dystrophies (MDs) are inherited genetic diseases causing weakness and degeneration of muscles. The distribution of muscle weakness differs between MDs, involving distal muscles or proximal muscles. While the mutations in most of the MD-associated genes lead to either distal or proximal onset, there are also genes whose mutations can cause both types of onsets. We hypothesized that the genes associated with different MD onsets code proteins with distinct cellular functions. To investigate this, we collected the MD-associated genes and assigned them to three onset groups: genes mutated only in distal onset dystrophies, genes mutated only in proximal onset dystrophies, and genes mutated in both types of onsets. We then systematically evaluated the cellular functions of these gene sets with computational strategies based on functional enrichment analysis and biological network analysis. Our analyses demonstrate that genes mutated in either distal or proximal onset MDs code proteins linked with two distinct sets of cellular processes. Interestingly, these two sets of cellular processes are relevant for the genes that are associated with both onsets. Moreover, the genes associated with both onsets display high centrality and connectivity in the network of muscular dystrophy genes. Our findings support the hypothesis that the proteins associated with distal or proximal onsets have distinct functional characteristics, whereas the proteins associated with both onsets are multifunctional., This work is supported by the funding from the European Union’s Horizon 2020 research and innovation programme under the EJP RD COFUND-EJP N° 825575., Peer Reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Solving patients with rare diseases through programmatic reanalysis of genome-phenome data

  • Matalonga, Leslie
  • Hernández Ferrer, Carles
  • Piscia, Davide
  • Tonda, Raúl
  • Laurie, Steven, 1973-
  • Fernández Callejo, Marcos
  • Picó, Daniel
  • Garcia-Linares, Carles
  • Papakonstantinou, Anastasios
  • Corvò, Alberto
  • Joshi, Ricky S.
  • Diez, Hector
  • Gut, Ivo Glynne
  • Beltran, Sergi
  • Solve-RD Consortium
Reanalysis of inconclusive exome/genome sequencing data increases the diagnosis yield of patients with rare diseases. However, the cost and efforts required for reanalysis prevent its routine implementation in research and clinical environments. The Solve-RD project aims to reveal the molecular causes underlying undiagnosed rare diseases. One of the goals is to implement innovative approaches to reanalyse the exomes and genomes from thousands of well-studied undiagnosed cases. The raw genomic data is submitted to Solve-RD through the RD-Connect Genome-Phenome Analysis Platform (GPAP) together with standardised phenotypic and pedigree data. We have developed a programmatic workflow to reanalyse genome-phenome data. It uses the RD-Connect GPAP's Application Programming Interface (API) and relies on the big-data technologies upon which the system is built. We have applied the workflow to prioritise rare known pathogenic variants from 4411 undiagnosed cases. The queries returned an average of 1.45 variants per case, which first were evaluated in bulk by a panel of disease experts and afterwards specifically by the submitter of each case. A total of 120 index cases (21.2% of prioritised cases, 2.7% of all exome/genome-negative samples) have already been solved, with others being under investigation. The implementation of solutions as the one described here provide the technical framework to enable periodic case-level data re-evaluation in clinical settings, as recommended by the American College of Medical Genetics., The Solve-RD project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779257. Data were analysed using the RD‐Connect Genome‐Phenome Analysis Platform, which received funding from EU projects RD‐Connect, Solve-RD and EJP-RD (grant numbers FP7 305444, H2020 779257, H2020 825575), Instituto de Salud Carlos III (grant numbers PT13/0001/0044, PT17/0009/0019; Instituto Nacional de Bioinformática, INB) and ELIXIR Implementation Studies.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Improved diagnosis of rare disease patients through systematic detection of runs of homozygosity

  • Matalonga, Leslie
  • Laurie, Steven, 1973-
  • Papakonstantinou, Anastasios
  • Piscia, Davide
  • Mereu, Elisabetta
  • Bullich, Gemma
  • Thompson, Rachel
  • Horvath, Rita
  • Pérez Jurado, Luis Alberto
  • Riess, Olaf
  • Gut, Ivo Glynne
  • van Ommen, Gert-Jan
  • Lochmüller, Hanns
  • Beltran, Sergi
  • RD–Connect Genome-Phenome Analysis Platform and URD-Cat Data Contributors
Autozygosity is associated with an increased risk of genetic rare disease, thus being a relevant factor for clinical genetic studies. More than 2400 exome sequencing data sets were analyzed and screened for autozygosity on the basis of detection of >1 Mbp runs of homozygosity (ROHs). A model was built to predict if an individual is likely to be a consanguineous offspring (accuracy, 98%), and probability of consanguinity ranges were established according to the total ROH size. Application of the model resulted in the reclassification of the consanguinity status of 12% of the patients. The analysis of a subset of 79 consanguineous cases with the Rare Disease (RD)-Connect Genome-Phenome Analysis Platform, combining variant filtering and homozygosity mapping, enabled a 50% reduction in the number of candidate variants and the identification of homozygous pathogenic variants in 41 patients, with an overall diagnostic yield of 52%. The newly defined consanguinity ranges provide, for the first time, specific ROH thresholds to estimate inbreeding within a pedigree on disparate exome sequencing data, enabling confirmation or (re)classification of consanguineous status, hence increasing the efficiency of molecular diagnosis and reporting on secondary consanguinity findings, as recommended by American College of Medical Genetics and Genomics guidelines., Supported by European Union projects RD-Connect, Solve-RD, and European Joint Programme of Rare Diseases (EJP-RD) grants FP7 305444, H2020 779257, and H2020 825575; Instituto de Salud Carlos III grants PT13/0001/0044 and PT17/0009/0019; Instituto Nacional de Bioinformática; ELIXIR Implementation Studies; European Union projects BBMRI-LPC EU FP7 313010, NeurOmics EU FP7 305121, and Undiagnosed Rare Disease Program of Catalonia (Departament de Salut, Generalitat de CatalunyaSLT002/16/00174); Canadian Institutes of Health Research Foundation grant FDN-167281 (H.L.); the European Research Council309548 (R.H.); the Wellcome Investigator Award 109915/Z/15/Z (R.H.); the Medical Research Council (United Kingdom) MR/N025431/1 (R.H.); the Wellcome Trust Pathfinder Scheme 201064/Z/16/Z (R.H. and H.L.); the Newton Fund (United Kingdom/Turkey) MR/N027302/1 (R.H. and H.L.); the Spanish Ministry of Economy, Industry and Competitiveness to the European Molecular Biology Laboratory (EMBL) partnership; the Centro de Excelencia Severo Ochoa; the Centres de Recerca de Catalunya (CERCA) Program/Generalitat de Catalunya; the Generalitat de Catalunya through the Department of Health and Department of Business and Knowledge; the Spanish Ministry of Economy, Industry and Competitiveness with funds from the European Regional Development Fund corresponding to the 2014 to 2020 Smart Growth Operating Program.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Twelve quick tips for deploying a Beacon

  • Fromont, Lauren A.
  • Moldes, Mauricio
  • Baudis, Michael
  • Brookes, Anthony J.
  • Navarro, Arcadi
  • Rambla de Argila, Jordi
This study was funded by ELIXIR, the research infrastructure for life-science data. The project leading to these results has also received funding and grant support from the “LaCaixa” Foundation under the Grant 004745/008034. LAF was supported, in part, by La Marató TV3, and has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101057182. AJB and JR received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 825575. MB acknowledges funding under the BioMedIT Network project of Swiss Institute of Bioinformatics (SIB) and Swiss Personalized Health Network (SPHN). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

System-level analysis of genes mutated in muscular dystrophies reveals a functional pattern associated with muscle weakness distribution

  • Ozisik, Ozan
  • Gorokhova, Svetlana
  • Cerino, Mathieu
  • Bartoli, Marc
  • Baudot, Anaïs
Muscular dystrophies (MDs) are inherited genetic diseases causing weakness and degeneration of muscles. The distribution of muscle weakness differs between MDs, involving distal muscles or proximal muscles. While the mutations in most of the MD-associated genes lead to either distal or proximal onset, there are also genes whose mutations can cause both types of onsets. We hypothesized that the genes associated with different MD onsets code proteins with distinct cellular functions. To investigate this, we collected the MD-associated genes and assigned them to three onset groups: genes mutated only in distal onset dystrophies, genes mutated only in proximal onset dystrophies, and genes mutated in both types of onsets. We then systematically evaluated the cellular functions of these gene sets with computational strategies based on functional enrichment analysis and biological network analysis. Our analyses demonstrate that genes mutated in either distal or proximal onset MDs code proteins linked with two distinct sets of cellular processes. Interestingly, these two sets of cellular processes are relevant for the genes that are associated with both onsets. Moreover, the genes associated with both onsets display high centrality and connectivity in the network of muscular dystrophy genes. Our findings support the hypothesis that the proteins associated with distal or proximal onsets have distinct functional characteristics, whereas the proteins associated with both onsets are multifunctional., This work is supported by the funding from the European Union’s Horizon 2020 research and innovation programme under the EJP RD COFUND-EJP N° 825575., Peer Reviewed, Postprint (published version)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Position paper on management of personal data in environment and health research in Europe

  • Govarts, Eva
  • Gilles, Liese
  • Bopp, Stephanie
  • Holub, Petr
  • Matalonga, Leslie
  • Vermeulen, Roel
  • Vrijheid, Martine
  • Beltran, Sergi
  • Hartlev, Mette
  • Jones, Sarah
  • Rodriguez Martin, Laura
  • Standaert, Arnout
  • Swertz, Morris A.
  • Theunis, Jan
  • Trier, Xenia
  • Vogel, Nina
  • Van Espen, Koert
  • Remy, Sylvie
  • Schoeters, Greet
Management of datasets that include health information and other sensitive personal information of European study participants has to be compliant with the General Data Protection Regulation (GDPR, Regulation (EU) 2016/679). Within scientific research, the widely subscribed'FAIR' data principles should apply, meaning that research data should be findable, accessible, interoperable and re-usable. Balancing the aim of open science driven FAIR data management with GDPR compliant personal data protection safeguards is now a common challenge for many research projects dealing with (sensitive) personal data. In December 2020 a workshop was held with representatives of several large EU research consortia and of the European Commission to reflect on how to apply the FAIR data principles for environment and health research (E&H). Several recent data intensive EU funded E&H research projects face this challenge and work intensively towards developing solutions to access, exchange, store, handle, share, process and use such sensitive personal data, with the aim to support European and transnational collaborations. As a result, several recommendations, opportunities and current limitations were formulated. New technical developments such as federated data management and analysis systems, machine learning together with advanced search software, harmonized ontologies and data quality standards should in principle facilitate the FAIRification of data. To address ethical, legal, political and financial obstacles to the wider re-use of data for research purposes, both specific expertise and underpinning infrastructure are needed. There is a need for the E&H research data to find their place in the European Open Science Cloud. Communities using health and population data, environmental data and other publicly available data have to interconnect and synergize. To maximize the use and re-use of environment and health data, a dedicated supporting European infrastructure effort, such as the EIRENE research infrastructure within the ESFRI roadmap 2021, is needed that would interact with existing infrastructures., HBM4EU is co-financed under Horizon 2020 (grant agreement No 733032). EUCAN-Connect is funded by the European Commission within the call topic SC1-BHC-05-2018: “International flagship collaboration with Canada for human data storage, integration and sharing to enable personalized medicine approaches” (Grant Agreement No 824989). The Canadian project partners have been funded by the Canadian Institutes of Health Research (CIHR) and the Fonds de recherche du Québec – Santé. The LifeCycle project received funding from the European Union’s Horizon 2020 research and innovation programme (Grant Agreement No. 733206 LifeCycle). The HELIX project received funding from the European Community’s Seventh Framework Programme (grant agreement no 308333 HELIX). ISGlobal acknowledges support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019-2023” Program (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Program. Roel Vermeulen is supported by EXPOSOME-NL and EXPANSE. EXPOSOME-NL is funded through the Gravitation program of the Dutch Ministry of Education, Culture, and Science and the Netherlands Organization for Scientific Research (NWO grant number 024.004.017). EXPANSE has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 874627. EOSC-Life project supported by EU Horizon 2020, grant agreement no. 824087. EJP-RD and Solve-RD projects have been financed under Horizon 2000 (grant numbers H2020 779257 and H2020 825575).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

FAIR Principles: Interpretations and Implementation Considerations

  • Jacobsen, Annika
  • Miranda Azevedo, Ricardo de
  • Juty, Nick
  • Batista, Dominique
  • Coles, Simon J.
  • Cornet, Ronald
  • Courtot, Mélanie
  • Crosas, Mercè
  • Dumontier, Michel
  • Evelo Chris, T.
  • Goble, Carole
  • Guizzardi, Giancarlo
  • Kryger-Hansen, Karsten
  • Hasnain, Ali
  • Hettne, Kristina
  • Heringa, Jaap
  • Hooft, Rob W. W.
  • Imming, Melanie
  • Jeffery, Keith G.
  • Kaliyaperumal, Rajaram
  • Kersloot, Martijn G.
  • Kirkpatrick, Christine R.
  • Kuhn, Tobias
  • Labastida i Juan, Ignasi, 1970-
  • Magagna, Barbara
  • McQuilton, Peter
  • Meyers, Natalie
  • Montesanti, Annalisa
  • van-Reisen, Mirjam
  • Rocca-Serra, Philippe
  • Pergl, Robert
  • Sansone, Susanna-Assunta
  • Bonino da Silva Santos, Luiz Olavo
  • Schneider, Juliane
  • Strawn, George
  • Thompson, Mark
  • Waagmeester, Andra
  • Weigel, Tobias
  • Wilkinson, Mark D.
  • Willighagen, Egon
The FAIR principles have been widely cited, endorsed and adopted by a broad range of stakeholders since their publication in 2016. By intention, the 15 FAIR guiding principles do not dictate specific technological implementations, but provide guidance for improving Findability, Accessibility, Interoperability and Reusability of digital resources. This has likely contributed to the broad adoption of the FAIR principles, because individual stakeholder communities can implement their own FAIR solutions. However, it has also resulted in inconsistent interpretations that carry the risk of leading to incompatible implementations. Thus, while the FAIR principles are formulated on a high level and may be interpreted and implemented in different ways, for true interoperability we need to support convergence in implementation choices that are widely accessible and (re)-usable. We introduce the concept of FAIR implementation considerations to assist accelerated global participation and convergence towards accessible, robust, widespread and consistent FAIR implementations. Any self-identified stakeholder community may either choose to reuse solutions from existing implementations, or when they spot a gap, accept the challenge to create the needed solution, which, ideally, can be used again by other communities in the future. Here, we provide interpretations and implementation considerations (choices and challenges) for each FAIR principle.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Remote visualization of large-scale genomic alignments for collaborative clinical research and diagnosis of rare diseases

  • Corvò, Alberto
  • Matalonga, Leslie
  • Laurie, Steven, 1973-
  • Picó-Amador, Daniel
  • Fernández Callejo, Marcos
  • Paramonov, Ida
  • Gut, Ivo Glynne
  • Piscia, Davide
  • Beltran, Sergi
The Solve-RD project objectives include solving undiagnosed rare diseases (RD) through collaborative research on shared genome-phenome datasets. The RD-Connect Genome-Phenome Analysis Platform (GPAP), for data collation and analysis, and the European Genome-Phenome Archive (EGA), for file storage, are two key components of the Solve-RD infrastructure. Clinical researchers can identify candidate genetic variants within the RD-Connect GPAP and, thanks to the developments presented here as part of joint ELIXIR activities, are able to remotely visualize the corresponding alignments stored at the EGA. The Global Alliance for Genomics and Health (GA4GH) htsget streaming application programming interface (API) is used to retrieve alignment slices, which are rendered by an integrated genome viewer (IGV) instance embedded in the GPAP. As a result, it is no longer necessary for over 11,000 datasets to download large alignment files to visualize them locally. This work highlights the advantages, from both the user and infrastructure perspectives, of implementing interoperability standards for establishing federated genomics data networks., This study was partially funded by ELIXIR Implementation Studies “Remote real-time visualization of human RDs genomics data (RD-Connect) stored at the EGA ELIXIR” (2017–2018), “Integration of ELIXIR-IIB in ELIXIR Rare Disease activities (2017–2018),” and “Rare Disease Infrastructure ELIXIR (2019–2020)” and the Solve-RD project, which received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement no. 779257. Data were analyzed using the RD-Connect Genome-Phenome Analysis Platform, which has received funding from EU projects RD-Connect, Solve-RD, and EJP-RD (grant nos. FP7 305444, H2020 779257, and H2020 825575), Instituto de Salud Carlos III (grant nos. PT13/0001/0044 and PT17/0009/0019; Instituto Nacional de Bioinformática, INB), and ELIXIR Implementation Studies. We acknowledge the support of the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Overlap of vitamin A and vitamin D target genes with CAKUT-related processes [version 2; peer review: 2 approved, 2 approved with reservations]

  • Ozisik, Ozan
  • Ehrhart, Friederike
  • Evelo, Chris T.
  • Mantovani, Alberto
  • Baudot, Anaı̈s
Congenital Anomalies of the Kidney and Urinary Tract (CAKUT) are a group of abnormalities affecting the kidneys and their outflow tracts. CAKUT patients display a large clinical variability as well as a complex aetiology. Only 5% to 20% of the cases have a monogenic origin. It is thereby suspected that interactions of both genetic and environmental factors contribute to the disease. Vitamins are among the environmental factors that are considered for CAKUT aetiology. In this study, we aimed to investigate whether vitamin A or vitamin D could have a role in CAKUT aetiology. For this purpose we collected vitamin A and vitamin D target genes and computed their overlap with CAKUT-related gene sets. We observed limited overlap between vitamin D targets and CAKUT-related gene sets. We however observed that vitamin A target genes significantly overlap with multiple CAKUT-related gene sets, including CAKUT causal and differentially expressed genes, and genes involved in renal system development. Overall, these results indicate that an excess or deficiency of vitamin A might be relevant to a broad range of urogenital abnormalities., Grant information: This study has been conducted in context of the European Joint Programme on Rare Diseases (EJP RD) which has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N°825575. Ozan Ozisik has received funding from the Excellence Initiative of Aix-Marseille University - A*Midex, a French “Investissements d’Avenir” programme., Peer Reviewed, Postprint (published version)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Improved diagnosis of rare disease patients through systematic detection of runs of homozygosity

  • Matalonga Borrel, Lesley
  • Laurie, Steven
  • Papakonstantinou, Anastasios
  • Piscia, Davide
  • Mereu, Elisabetta
  • Bullich, Gemma
  • Thompson, Rachel
  • Horvath, Rita
  • Pérez Jurado, Luis A.
  • Riess, Olaf
  • Gut, Ivo
  • van Ommen, Gert Jan
  • Lochmüller, Hanns
  • Beltrán, Sergi
  • Rare Disease-Connect Genome-Phenome Analysis Platform data contributors
  • Undiagnosed Rare Disease Programme of Catalonia data contibutors
  • Cormand Rifà, Bru
  • Balcells Comas, Susana
  • Grinberg Vaisman, Daniel Raúl
  • Urreizti, Roser
  • Garrabou Tornos, Glòria
Autozygosity is associated with an increased risk of genetic rare disease, thus being a relevant factor for clinical genetic studies. More than 2400 exome sequencing data sets were analyzed and screened for autozygosity on the basis of detection of >1 Mbp runs of homozygosity (ROHs). A model was built to predict if an individual is likely to be a consanguineous offspring (accuracy, 98%), and probability of consanguinity ranges were established according to the total ROH size. Application of the model resulted in the reclassification of the consanguinity status of 12% of the patients. The analysis of a subset of 79 consanguineous cases with the Rare Disease (RD)-Connect Genome-Phenome Analysis Platform, combining variant filtering and homozygosity mapping, enabled a 50% reduction in the number of candidate variants and the identification of homozygous pathogenic variants in 41 patients, with an overall diagnostic yield of 52%. The newly defined consanguinity ranges provide, for the first time, specific ROH thresholds to estimate inbreeding within a pedigree on disparate exome sequencing data, enabling confirmation or (re)classification of consanguineous status, hence increasing the efficiency of molecular diagnosis and reporting on secondary consanguinity findings, as recommended by American College of Medical Genetics and Genomics guidelines
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Solving unsolved rare neurological diseases-a Solve-RD viewpoint

  • Matalonga, Leslie
  • Timmann, Dagmar
  • Erasmus, Corrie E.
  • Reichbauer, Jennifer
  • Wayand, Melanie
  • Solve-RD-DITF-RND
  • van de Warrenburg, Bart
  • Schöls, Ludger
  • Wilke, Carlo
  • Bevot, Andrea
  • Zuchner, Stephan
  • Beltran, Sergi
  • Laurie, Steven, 1973-
  • Matalonga, Leslie
  • Graessner, Holm
  • Synofzik, Matthis
  • Solve-RD Consortium
Rare genetic neurological disorders (RND; ORPHA:71859) are a heterogeneous group of disorders comprising >1700 distinct genetic disease entities. However, genetic discoveries have not yet translated into dramatic increases of diagnostic yield and indeed rates of molecular genetic diagnoses have been stuck at about 30–50% across NGS modalities and RND phenotypes [1, 2]. Existence of yet unknown disease genes as well as shortcomings of commonly employed NGS technologies and analysis pipelines in detecting certain variant types are typically cited to explain the low diagnosis rates. To increase the diagnostic yield in RNDs - one of the four focus disease groups in Solve-RD - we follow two major approaches, that we will here present and exemplify: (i) systematic state-of the art re-analysis of large cohorts of unsolved whole-exome/genome sequencing (WES/WGS) RND datasets; and (ii) novel-omics approaches. Based on the way Solve-RD systematically organizes researchers’ expertise to channel this approach [3], the European Reference Network for Rare Neurological Diseases (ERN-RND) has established its own Data Interpretation Task Force (DITF) within SOLVE-RD, which is currently composed of clinical and genetic experts from 29 sites in 15 European countries., The Solve-RD project has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No. 779257. Data were analysed using the RD‐Connect Genome‐Phenome Analysis Platform, which received funding from EU projects RD‐Connect, Solve-RD and EJP-RD (Grant Numbers FP7 305444, H2020 779257, H2020 825575), Instituto de Salud Carlos III (Grant Numbers PT13/0001/0044, PT17/0009/0019; Instituto Nacional de Bioinformática, INB) and ELIXIR Implementation Studies. The study was further funded by the Federal Ministry of Education and Research, Germany, through the TreatHSP network (01GM1905 to RS and LS), the National Institute of Neurological Diseases and Stroke (R01NS072248 to SZ and RS), the European Joint Program on Rare Diseases-EJP-RD COFUND-EJP N° 825575 through funding for the PROSPAX consortium (441409627 to MS, RS and BvW). CW was supported by the PATE program of the Medical Faculty, University of Tübingen. CEE received support from the Dutch Princess Beatrix Muscle Fund and the Dutch Spieren voor Spieren Muscle fund. Authors on this paper are members of the European Reference Network for Rare Neurological Diseases (ERN-RND, Project ID 739510)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Standards of NGS data sharing and analysis in Ataxias: recommendations by the NGS Working Group of the Ataxia Global Initiative

  • Beijer, Danique
  • Fogel, Brent L.
  • Beltran, Sergi
  • Danzi, Matt C.
  • Németh, Andrea H.
  • Züchner, Stephan
  • Synofzik, Matthis
  • AGI Ataxia NGS genomics, platforms Working Group
The Ataxia Global Initiative (AGI) is a worldwide multi-stakeholder research platform to systematically enhance trial-readiness in degenerative ataxias. The next-generation sequencing (NGS) working group of the AGI aims to improve methods, platforms, and international standards for ataxia NGS analysis and data sharing, ultimately allowing to increase the number of genetically ataxia patients amenable for natural history and treatment trials. Despite extensive implementation of NGS for ataxia patients in clinical and research settings, the diagnostic gap remains sizeable, as approximately 50% of patients with hereditary ataxia remain genetically undiagnosed. One current shortcoming is the fragmentation of patients and NGS datasets on different analysis platforms and databases around the world. The AGI NGS working group in collaboration with the AGI associated research platforms—CAGC, GENESIS, and RD-Connect GPAP—provides clinicians and scientists access to user-friendly and adaptable interfaces to analyze genome-scale patient data. These platforms also foster collaboration within the ataxia community. These efforts and tools have led to the diagnosis of > 500 ataxia patients and the discovery of > 30 novel ataxia genes. Here, the AGI NGS working group presents their consensus recommendations for NGS data sharing initiatives in the ataxia field, focusing on harmonized NGS variant analysis and standardized clinical and metadata collection, combined with collaborative data and analysis tool sharing across platforms., Open Access funding enabled and organized by Projekt DEAL. This work was supported by the Horizon 2020 research and innovation programme (grant 779257 Solve-RD to MS and SB), and the European Joint Programme on Rare Diseases (grant 825575 EJP RD to SB) under the EJP RD COFUND-EJP No. 825575 (PROSPAX consortium, to MS and—as an associated partner—SZ). DB is supported by a Postdoctoral Fellowship from the Alexander von Humboldt Foundation.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The data use ontology to streamline responsible access to human biomedical datasets

  • Lawson, Jonathan
  • Jene, Aina
  • Rambla de Argila, Jordi
  • Courtot, Mélanie
Human biomedical datasets that are critical for research and clinical studies to benefit human health also often contain sensitive or potentially identifying information of individual participants. Thus, care must be taken when they are processed and made available to comply with ethical and regulatory frameworks and informed consent data conditions. To enable and streamline data access for these biomedical datasets, the Global Alliance for Genomics and Health (GA4GH) Data Use and Researcher Identities (DURI) work stream developed and approved the Data Use Ontology (DUO) standard. DUO is a hierarchical vocabulary of human and machine-readable data use terms that consistently and unambiguously represents a dataset's allowable data uses. DUO has been implemented by major international stakeholders such as the Broad and Sanger Institutes and is currently used in annotation of over 200,000 datasets worldwide. Using DUO in data management and access facilitates researchers' discovery and access of relevant datasets. DUO annotations increase the FAIRness of datasets and support data linkages using common data use profiles when integrating the data for secondary analyses. DUO is implemented in the Web Ontology Language (OWL) and, to increase community awareness and engagement, hosted in an open, centralized GitHub repository. DUO, together with the GA4GH Passport standard, offers a new, efficient, and streamlined data authorization and access framework that has enabled increased sharing of biomedical datasets worldwide., G.K., M.A.F., H.P., J.D.S., and M.C. were funded by EMBL-EBI Core Funds and Wellcome Trust GA4GH award number 201535/Z/16/Z. T. T. Boughtwood was funded by NHMRC GNT111353, GNT200001, and the Australian MRFF. P.A. was funded by ELIXIR Luxembourg. S.D. and K.R. were funded by the Broad Institute. M.A.H. and M.B. received funding from NIH #5R24OD011883. M.L. and M.C. were funded by the CINECA project (H2020 No 825775). N.M. and L.Z. were funded by H3ABioNet, NIH grant number U24HG006941. S.O. and C.Y. received funding from the Japan Agency for Medical Research and Development (AMED) under grant numbers JP19kk020501 and JP18kk0205012. A.A.P. was funded by NHGRI AnVIL, award number U24HG010262. F.P. was supported, in part, by the European Union’s Horizon 2020 research and innovation program under the EJP RD COFUND-EJP #825575. M.A.S. and E.J.v.E. were funded by FAIR genomes (ZonMW #846003201) and EOSC-Life (H2020 #824087)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The 'A' of FAIR - As Open as Possible, as Closed as Necessary

  • Landi, Annalisa
  • Thompson, Mark
  • Giannuzzi, Viviana
  • Bonifazi, Fedele
  • Labastida i Juan, Ignasi, 1970-
  • Bonino da Silva Santos, Luiz Olavo
  • Roos, Marco
In order to provide responsible access to health data by reconciling benefits of data sharing with privacy rights and ethical and regulatory requirements, Findable, Accessible, Interoperable and Reusable (FAIR) metadata should be developed. According to the H2020 Program Guidelines on FAIR Data, data should be 'as open as possible and as closed as necessary', 'open' in order to foster the reusability and to accelerate research, but at the same time they should be 'closed' to safeguard the privacy of the subjects. Additional provisions on the protection of natural persons with regard to the processing of personal data have been endorsed by the European General Data Protection Regulation (GDPR), Reg (EU) 2016/679, that came into force in May 2018. This work aims to solve accessibility problems related to the protection of personal data in the digital era and to achieve a responsible access to and responsible use of health data. We strongly suggest associating each data set with FAIR metadata describing both the type of data collected and the In order to provide responsible access to health data by reconciling benefits of data sharing with privacy rights and ethical and regulatory requirements, Findable, Accessible, Interoperable and Reusable (FAIR) metadata should be developed. According to the H2020 Program Guidelines on FAIR Data, data should be 'as open as possible and as closed as necessary', 'open' in order to foster the reusability and to accelerate research, but at the same time they should be 'closed' to safeguard the privacy of the subjects. Additional provisions on the protection of natural persons with regard to the processing of personal data have been endorsed by the European General Data Protection Regulation (GDPR), Reg (EU) 2016/679, that came into force in May 2018. This work aims to solve accessibility problems related to the protection of personal data in the digital era and to achieve a responsible access to and responsible use of health data. We strongly suggest associating each data set with FAIR metadata describing both the type of data collected and the accessibility conditions by considering data protection obligations and ethical and regulatory requirements. Finally, an existing FAIR infrastructure component has been used as an example to explain how FAIR metadatacould facilitate data sharing while ensuring protection of individuals.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Beacon v2 and Beacon networks: A "lingua franca" for federated data discovery in biomedical genomics, and beyond

  • Rambla de Argila, Jordi
  • Baudis, Michael
  • Ariosa, Roberto
  • Beck, Timothy
  • Fromont, Lauren A.
  • Navarro i Cuartiellas, Arcadi, 1969-
  • Paloots, Rahel
  • Rueda, Manuel
  • Saunders, Gary
  • Singh, Babita, 1986-
  • Spalding, J. Dylan
  • Törnoos, Juha
  • Vasallo, Claudia
  • Veal, Colin D.
  • Brookes, Anthony J.
Beacon is a basic data discovery protocol issued by the Global Alliance for Genomics and Health (GA4GH). The main goal addressed by version 1 of the Beacon protocol was to test the feasibility of broadly sharing human genomic data, through providing simple "yes" or "no" responses to queries about the presence of a given variant in datasets hosted by Beacon providers. The popularity of this concept has fostered the design of a version 2, that better serves real-world requirements and addresses the needs of clinical genomics research and healthcare, as assessed by several contributing projects and organizations. Particularly, rare disease genetics and cancer research will benefit from new case level and genomic variant level requests and the enabling of richer phenotype and clinical queries as well as support for fuzzy searches. Beacon is designed as a "lingua franca" to bridge data collections hosted in software solutions with different and rich interfaces. Beacon version 2 works alongside popular standards like Phenopackets, OMOP, or FHIR, allowing implementing consortia to return matches in beacon responses and provide a handover to their preferred data exchange format. The protocol is being explored by other research domains and is being tested in several international projects., This study was funded by ELIXIR, the research infrastructure for lifescience data and also by La Caixa Foundation (grant number 004745/ 008034). Tim Beck was supported by a UKRI Innovation Fellowship at Health Data Research UK (MR/S003703/1). Anthony J. Brookes and Jordi Rambla were supported, in part, by the European Union's Horizon 2020 research and innovation program under the EJP RD COFUND‐EJP #825575. Michael Baudis acknowledges funding under the BioMedIT Network project of Swiss Institute of Bioinformatics (SIB) and Swiss Personalized Health Network (SPHN)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

NOTCH3 Variant Position Affects the Phenotype at the Pluripotent Stem Cell Level in CADASIL

  • bugallo, ana
  • Muiño, Elena
  • Hervella, Pablo
  • Arias-Rivas, Susana
  • Rodríguez-Yáñez, Manuel
  • Maisterra Santos, Olga
  • Pizarro Gonzálvez, Jesús
  • Bravo Lopez, Susana Belén
Disease modeling; Proteomic analysis; Stem cells, Modelització de malalties; Anàlisi proteòmica; Cèl·lules mare, Modelado de enfermedades; Análisis proteómico; Células madre, Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common genetic form of stroke. It is caused by a cysteine-altering variant in one of the 34 epidermal growth factor-like repeat (EGFr) domains of Notch3. NOTCH3 pathogenic variants in EGFr 1–6 are associated with high disease severity, whereas those in EGFr 7–34 are associated with late stroke onset and increased survival. However, whether and how the position of the NOTCH3 variant directly affects the disease severity remains unclear. In this study, we aimed to generate human-induced pluripotent stem cells (hiPSCs) from patients with CADASIL with EGFr 1–6 and 7–34 pathogenic variants to evaluate whether the NOTCH3 position affects the cell phenotype and protein profile of the generated hiPSCs lines. Six hiPSCs lines were generated: two from patients with CADASIL with EGFr 1–6 pathogenic variants, two from patients with EGFr 7–34 variants, and two from controls. Notch3 aggregation and protein profiles were tested in the established six hiPSCs lines. Cell analysis revealed that the NOTCH3 variants did not limit the cell reprogramming efficiency. However, EGFr 1–6 variant position was associated with increased accumulation of Notch3 protein in pluripotent stem cells and proteomic changes related with cytoplasmic reorganization mechanisms. In conclusion, our analysis of hiPSCs derived from patients with CADASIL support the clinical association between the NOTCH3 variant position and severity of CADASIL., This study has been funded by Instituto de Salud Carlos III (ISCIII) through the project PI17/00540, PI20/01014, PI23/000890, RICORS-ICITUS RD21/0006/0003, RD21/0006/0004, RD24/0009/0022, RD24/0009/0017 and AC23-2/00029. AC23-2/00029 (named as CADANHIS) project has been supported by the EJP RD—European Joint Programme on Rare Diseases—Joint Transnational Call 2023 for Rare Diseases Research Project (JTC 2023). The EJP RD initiative has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement N°825575. Finally, this work was supported by grants from the Instituto de Salud Carlos III, PReDICT Project (PMPER24/00021) together with Next-Generation EU funds that finance the actions of the Recovery and Resilience Mechanism.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A Solve-RD ClinVar-based reanalysis of 1522 index cases from ERN-ITHACA reveals common pitfalls and misinterpretations in exome sequencing

  • Denommé-Pichon, Anne-Sophie
  • Matalonga, Leslie
  • Faivre, Laurence
Purpose: Within the Solve-RD project (https://solve-rd.eu/), the European Reference Network for Intellectual disability, TeleHealth, Autism and Congenital Anomalies aimed to investigate whether a reanalysis of exomes from unsolved cases based on ClinVar annotations could establish additional diagnoses. We present the results of the "ClinVar low-hanging fruit" reanalysis, reasons for the failure of previous analyses, and lessons learned. Methods: Data from the first 3576 exomes (1522 probands and 2054 relatives) collected from European Reference Network for Intellectual disability, TeleHealth, Autism and Congenital Anomalies was reanalyzed by the Solve-RD consortium by evaluating for the presence of single-nucleotide variant, and small insertions and deletions already reported as (likely) pathogenic in ClinVar. Variants were filtered according to frequency, genotype, and mode of inheritance and reinterpreted. Results: We identified causal variants in 59 cases (3.9%), 50 of them also raised by other approaches and 9 leading to new diagnoses, highlighting interpretation challenges: variants in genes not known to be involved in human disease at the time of the first analysis, misleading genotypes, or variants undetected by local pipelines (variants in off-target regions, low quality filters, low allelic balance, or high frequency). Conclusion: The "ClinVar low-hanging fruit" analysis represents an effective, fast, and easy approach to recover causal variants from exome sequencing data, herewith contributing to the reduction of the diagnostic deadlock., The Solve-RD project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement number 779257. Data were analyzed using the RD-Connect Genome-Phenome Analysis Platform, which received funding from the EU projects RD-Connect, Solve-RD, and European Joint Programme on Rare Diseases (grant numbers FP7 305444, H2020 779257, H2020 825575), Instituto de Salud Carlos III (grant numbers PT13/0001/0044, PT17/0009/0019; Instituto Nacional de Bioinformática), and ELIXIR Implementation Studies. The collaborations in this study were facilitated by the European Reference Network for Intellectual disability, TeleHealth, Autism and Congenital Anomalies, one of the 24 European Reference Networks approved by the European Reference Network Board of Member States, cofunded by the European Commission. This project was supported by the Czech Ministry of Health (number 00064203) and by the Czech Ministry of Education, Youth and Sports (number - LM2018132) to M.M.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The RD-Connect Genome-Phenome Analysis Platform: Accelerating diagnosis, research, and gene discovery for rare diseases

  • Laurie, Steven, 1973-
  • Piscia, Davide
  • Matalonga, Leslie
  • Corvò, Alberto
  • Fernández Callejo, Marcos
  • Garcia-Linares, Carles
  • Hernandez-Ferrer, Carles, 1987-
  • Luengo, Cristina
  • Martínez, Inés
  • Papakonstantinou, Anastasios
  • Picó-Amador, Daniel
  • Protasio, Joan
  • Tonda, Raúl
  • Bayés, Mònica
  • Bullich, Gemma
  • Camps-Puchadas, Jordi
  • Paramonov, Ida
  • Trotta, Jean-Remi
  • Pérez Jurado, Luis Alberto
  • Rambla de Argila, Jordi
  • Gut, Ivo Glynne
  • Lochmüller, Hanns
  • Beltran, Sergi
Rare disease patients are more likely to receive a rapid molecular diagnosis nowadays thanks to the wide adoption of next-generation sequencing. However, many cases remain undiagnosed even after exome or genome analysis, because the methods used missed the molecular cause in a known gene, or a novel causative gene could not be identified and/or confirmed. To address these challenges, the RD-Connect Genome-Phenome Analysis Platform (GPAP) facilitates the collation, discovery, sharing, and analysis of standardized genome-phenome data within a collaborative environment. Authorized clinicians and researchers submit pseudonymised phenotypic profiles encoded using the Human Phenotype Ontology, and raw genomic data which is processed through a standardized pipeline. After an optional embargo period, the data are shared with other platform users, with the objective that similar cases in the system and queries from peers may help diagnose the case. Additionally, the platform enables bidirectional discovery of similar cases in other databases from the Matchmaker Exchange network. To facilitate genome-phenome analysis and interpretation by clinical researchers, the RD-Connect GPAP provides a powerful user-friendly interface and leverages tens of information sources. As a result, the resource has already helped diagnose hundreds of rare disease patients and discover new disease causing genes., We acknowledge the support of the developers of PhenoTips, which was used in the past by RD-Connect and NeurOmics as the primary tool to collate phenotypic data. We would also like to thank the leaders and members of the Instituto Nacional de Bioinformática (INB) and ELIXIR for their support and collaboration throughout the years. RD-Connect (RD-Connect, an integrated platform connecting registries, biobanks, and clinical bioinformatics) received funding from the Seventh Framework (FP7) Programme of the European Union under grant agreement No 305444. Data were analyzed using the RD-Connect GPAP, which received funding from EU projects Solve-RD, EJP-RD (grant numbers H2020 779257, H2020 825575), Instituto de Salud Carlos III (Grant numbers PT13/0001/0044, PT17/0009/0019; Instituto Nacional de Bioinformática, INB), ELIXIR-EXCELERATE (Grant number EU H2020 #676559) and ELIXIR Implementation Studies (Remote real-time visualization of human rare disease genomics data (RD-Connect) stored at the EGA ELIXIR. 2017-2018; ELIXIR IT-2017-INTEGRATION, Rare Disease Infrastructure ELIXIR, 2019-2020 and the Beacon ELIXIR, 2019-2021). The RD-Connect GPAP has leveraged developments funded through project VEIS (001-P-001647 co-financed by the European Regional Development Fund of the European Union in the framework of the Operational Program FEDER of Catalonia 2014-2020 with the support of the Secretaria d'Universitats i Recerca del Departament d'Empresa i Coneixement de la Generalitat de Catalunya) and URD-Cat (PERIS SLT002/16/00174, Departament de Salut, Generalitat de Catalunya). The research leading to these results has received funding from Consequitur (Newton Fund UK/Turkey, MR/N027302/1), BBMRI-LPC (EU FP7 #313010), NeurOmics (EU FP7 #305121), the Economic Development Department of the Navarra Government (Grant number 001114112017), the European Reference Network for Rare Neurological Diseases (Project ID number 739510) and NIH, National Institute of Child Health and Human Development (1R01HD103805-01). We acknowledge the support of the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Program/Generalitat de Catalunya. We also acknowledge the support of the Generalitat de Catalunya through Departament de Salut and Departament d'Empresa i Coneixement and Co-financing by the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) with funds from the European Regional Development Fund (ERDF) corresponding to the 2014-2020 Smart Growth Operating Program. HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A mosaic PIK3CA variant in a young adult with diffuse gastric cancer: case report

  • Te Paske, Iris B.A.W.
  • Garcia-Pelaez, José
  • Sommer, Anna K.
  • Matalonga, Leslie
  • Starzynska, Teresa
  • Jakubowska, Anna
  • Solve-RD-GENTURIS group
  • van der Post, Rachel S.
  • Lubinski, Jan
  • Oliveira, Carla
  • Hoogerbrugge, Nicoline
  • de Voer, Richarda M.
Hereditary diffuse gastric cancer (HDGC) is associated with germline deleterious variants in CDH1 and CTNNA1. The majority of HDGC-suspected patients are still genetically unresolved, raising the need for identification of novel HDGC predisposing genes. Under the collaborative environment of the SOLVE-RD consortium, re-analysis of whole-exome sequencing data from unresolved gastric cancer cases (n = 83) identified a mosaic missense variant in PIK3CA in a 25-year-old female with diffuse gastric cancer (DGC) without familial history for cancer. The variant, c.3140A>G p.(His1047Arg), a known cancer-related somatic hotspot, was present at a low variant allele frequency (18%) in leukocyte-derived DNA. Somatic variants in PIK3CA are usually associated with overgrowth, a phenotype that was not observed in this patient. This report highlights mosaicism as a potential, and understudied, mechanism in the etiology of DGC., The Solve-RD project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779257. The research work at i3S/Ipatimup is supported by the European Regional Development Fund (ERDF) through COMPETE 2020 - Operacional Programme for Competitiveness and Internationalisation (POCI), Portugal 2020, and by Portuguese funds through FCT/ Ministério da Ciência, Tecnologia e Inovação in the framework of the project “Institute for Research and Innovation in Health Sciences” (POCI-01-0145-FEDER-007274) and Project Ref. POCI-01-0145-FEDER-030164. Data was reanalysed using the RD‐Connect Genome‐Phenome Analysis Platform, which received funding from EU projects RD‐Connect, Solve-RD and EJP-RD (grant numbers FP7 305444, H2020 779257, H2020 825575), Instituto de Salud Carlos III (grant numbers PT13/0001/0044, PT17/0009/0019; Instituto Nacional de Bioinformática, INB) and ELIXIR Implementation Studies.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Increasing phenotypic annotation improves the diagnostic rate of exome sequencing in a rare neuromuscular disorder

  • Thompson, Rachel
  • Papakonstantinou, Anastasios
  • Beltran, Sergi
  • Topf, Ana
  • de Paula Estephan, Eduardo
  • Poloavarapu, Kiran
  • Hoen, Peter A. C.
  • Missier, Paolo
  • Lochmüller, Hanns
Phenotype-based filtering and prioritization contribute to the interpretation of genetic variants detected in exome sequencing. However, it is currently unclear how extensive this phenotypic annotation should be. In this study, we compare methods for incorporating phenotype into the interpretation process and assess the extent to which phenotypic annotation aids prioritization of the correct variant. Using a cohort of 29 patients with congenital myasthenic syndromes with causative variants in known or newly discovered disease genes, exome data and the Human Phenotype Ontology (HPO)-coded phenotypic profiles, we show that gene-list filters created from phenotypic annotations perform similarly to curated disease-gene virtual panels. We use Exomiser, a prioritization tool incorporating phenotypic comparisons, to rank candidate variants while varying phenotypic annotation. Analyzing 3,712 combinations, we show that increasing phenotypic annotation improved prioritization of the causative variant, from 62% ranked first on variant alone to 90% with seven HPO annotations. We conclude that any HPO-based phenotypic annotation aids variant discovery and that annotation with over five terms is recommended in our context. Although focused on a constrained cohort, this provides real-world validation of the utility of phenotypic annotation for variant prioritization. Further research is needed to extend this concept to other diseases and more diverse cohorts., Data was analyzed using the RD‐Connect Genome‐Phenome Analysis Platform developed under the 2012‐2018 FP7‐funded project RD‐ Connect (Grant Agreement No.: 305444). R. T., S. B., A. P. N., P. tH., and H. L. received support from the EU FP7 projects 305444 (RD‐ Connect) and 305121 (NeurOmics). S. B. received support from the EU FP7 project 313010 (BBMRI‐LPC). S. B. and P. tH. received support from the EU Horizon 2020 project 779257 (Solve‐RD). S. B., P. tH., and H. L. received support from the EU Horizon 2020 project 825575 (EJP‐RD). H. L. is supported by a project grant of the Canadian Institutes of Health Research (CIHR PJT 162265)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Systematic collaborative reanalysis of genomic data improves diagnostic yield in neurologic rare diseases

  • Bullich, Gemma
  • Matalonga, Leslie
  • Pujadas, Montserrat
  • Papakonstantinou, Anastasios
  • Piscia, Davide
  • Tonda, Raúl
  • González, Juan Ramón
  • Laurie, Steven, 1973-
  • Luengo, Cristina
  • Ovelleiro, David
  • Parra Farré, Genís
  • Pérez Jurado, Luis Alberto
  • Beltran, Sergi
  • Undiagnosed Rare Disease Program of Catalonia (URD-Cat) Consortium
Many patients experiencing a rare disease remain undiagnosed even after genomic testing. Reanalysis of existing genomic data has shown to increase diagnostic yield, although there are few systematic and comprehensive reanalysis efforts that enable collaborative interpretation and future reinterpretation. The Undiagnosed Rare Disease Program of Catalonia project collated previously inconclusive good quality genomic data (panels, exomes, and genomes) and standardized phenotypic profiles from 323 families (543 individuals) with a neurologic rare disease. The data were reanalyzed systematically to identify relatedness, runs of homozygosity, consanguinity, single-nucleotide variants, insertions and deletions, and copy number variants. Data were shared and collaboratively interpreted within the consortium through a customized Genome-Phenome Analysis Platform, which also enables future data reinterpretation. Reanalysis of existing genomic data provided a diagnosis for 20.7% of the patients, including 1.8% diagnosed after the generation of additional genomic data to identify a second pathogenic heterozygous variant. Diagnostic rate was significantly higher for family-based exome/genome reanalysis compared with singleton panels. Most new diagnoses were attributable to recent gene-disease associations (50.8%), additional or improved bioinformatic analysis (19.7%), and standardized phenotyping data integrated within the Undiagnosed Rare Disease Program of Catalonia Genome-Phenome Analysis Platform functionalities (18%)., Supported by Generalitat de Catalunya through Departament de Salut (SLT002/16/00174 to URD-Cat consortium) and Departament d’Empresa i Coneixement and the CERCA Program; FP7 and H2020 EU projects RD-Connect, Solve-RD, and EJP-RD grants FP7 305444, H2020 779257, and H2020 825575 for CNAG-CRG; Spanish Ministry of Science and Innovation to the EMBL partnership and through the Instituto de Salud Carlos III grants PT13/0001/0044 and PT17/0009/0019 for CNAG-CRG and grants PI16/01048, PI19/01310, PI18/00451, PI18/00498, and PI21/00935 for IDIBAPS (Instituto Nacional de Bioinformática); ELIXIR Implementation Studies (CNAG-CRG); Centro de Investigaciones Biomédicas en Red de Enfermedades Raras; Centro de Excelencia Severo Ochoa grant SEV-2016-0571 (CNAG-CRG) and grant CEX 2018-000806-S (ISGLOBAL); and cofinancing with funds from the European Regional Development Fund by the Spanish Ministry of Science and Innovation corresponding to the Programa Operativo FEDER Plurirregional de España (POPE) 2014 to 2020 and by the Secretaria d’Universitats i Recerca, Departament d’Empresa i Coneixement of the Generalitat de Catalunya corresponding to the Programa Operatiu FEDER de Catalunya 2014 to 2020.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The European Genome-phenome Archive in 2021

  • Freeberg, Mallory Ann
  • Fromont, Lauren A.
  • D&apos;Altri, Teresa, 1984-
  • Jene, Aina
  • Moldes, Mauricio
  • Ariosa, Roberto
  • Fernández-Orth, Dietmar
  • Haziza, Frédéric
  • Martinez Llobet, Oscar
  • Milla, Gemma
  • Rueda, Manuel
  • Singh, Babita, 1986-
  • Torre, Sabela de la
  • Uyan, Umuthan
  • Vasallo, Claudia
  • Guigó Serra, Roderic
  • Navarro i Cuartiellas, Arcadi, 1969-
  • Rambla de Argila, Jordi
The European Genome-phenome Archive (EGA - https://ega-archive.org/) is a resource for long term secure archiving of all types of potentially identifiable genetic, phenotypic, and clinical data resulting from biomedical research projects. Its mission is to foster hosted data reuse, enable reproducibility, and accelerate biomedical and translational research in line with the FAIR principles. Launched in 2008, the EGA has grown quickly, currently archiving over 4,500 studies from nearly one thousand institutions. The EGA operates a distributed data access model in which requests are made to the data controller, not to the EGA, therefore, the submitter keeps control on who has access to the data and under which conditions. Given the size and value of data hosted, the EGA is constantly improving its value chain, that is, how the EGA can contribute to enhancing the value of human health data by facilitating its submission, discovery, access, and distribution, as well as leading the design and implementation of standards and methods necessary to deliver the value chain. The EGA has become a key GA4GH Driver Project, leading multiple development efforts and implementing new standards and tools, and has been appointed as an ELIXIR Core Data Resource., Horizon 2020 Programme of the European Union [CORBEL [654248], ELIXIR-EXCELERATE [676559], Solve-RD [779257], EASI-Genomics [824110], EJP-RD [825575], CINECA [825775], EuCanCan [825835], EUCanshare [825903], ELIXIR-CONVERGE [871075]]; Wellcome Trust Global Alliance for Genomics and Health [201535/Z/16/Z]; UK Biobank; Chan Zuckerberg Initiative DAF, an advised fund of Silicon Valley Community Foundation [2017-171304 (5022)]; European Molecular Biology Laboratory (EMBL); LaCaixa Foundation [004745/008034]; [LCF/PR/CE20/50740008]. Funding for open access charge: LaCaixa Foundation [LCF/PR/CE20/50740008].
Archivo Digital UPM
Publication Artículo científico (JournalArticle)

Evaluating FAIR maturity through a scalable, automated, community-governed framework

Archivo Digital UPM
Publication Tesis doctoral (DoctoralThesis)

FAIR metadata, models, and interfaces to support machine-readable data access and use conditions

Archivo Digital UPM
Publication Tesis doctoral (DoctoralThesis)

Applying deep semantics to the representation of clinical data to improve machine usability

Archivo Digital UPM
Publication Artículo científico (JournalArticle)

The FLAIR-GG federated network of FAIR germplasm data resources

  • Cámara Ballesteros, Alberto|||0000-0001-5613-9704
  • Aguado Jara, Elena
  • Verykaki, Evrykleia Sofía|||0009-0003-5636-6183
  • Pastor del Olmo, Germán|||0009-0006-4001-8928
  • Moreno Vazquez, Santiago|||0000-0002-6595-8987
  • Torres Lamas, M Elena|||0000-0002-5906-977X
  • Wilkinson, Mark Denis|||0000-0001-6960-357X
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Systematic Collaborative Reanalysis of Genomic Data Improves Diagnostic Yield in Neurologic Rare Diseases

  • Bullich Vilanova, Gemma|||0000-0002-0737-4422
  • Matalonga, Leslie
  • Pujadas, Montserrat
  • Papakonstantinou, Anastasios
  • Piscia, Davide
  • Tonda, Raúl
  • Artuch, R.|||0000-0002-3422-9685
  • Gallano, Pia|||0000-0001-8104-2197
  • Garrabou, Glòria|||0000-0001-8973-9933
  • González, Juan R.|||0000-0003-3267-2146
  • Grinberg, Daniel|||0000-0001-9859-2590
  • Guitart, Maria|||0000-0003-2957-7404
  • Laurie, Steven|||0000-0003-3913-5829
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Luengo, Cristina
  • Martí, Ramon A.|||0000-0002-8273-9540
  • Milà, Montserrat
  • Ovelleiro, David|||0000-0002-9415-2229
  • Parra, Genís
  • Pujol, Aurora|||0000-0002-9606-0600
  • Tizzano, Eduardo F.|||0000-0002-7116-6310
  • Macaya Ruiz, Alfons|||0000-0001-7998-4185
  • Palau, Francesc|||0000-0002-8635-5421
  • Ribes, Antònia
  • Pérez-Jurado, Luis Alberto|||0000-0002-1988-3005
  • Beltran i Agulló, Sergi|||0000-0002-2810-3445
  • Schlüter, Agatha|||0000-0001-6732-1528
  • Rodríguez-Palmero, Agustí|||0000-0002-4141-5515
  • Cáceres, Alejandro|||0000-0001-8551-6695
  • Nascimento, Andrés
  • García-Cazorla, Àngels
  • Cueto-González, Anna Mª|||0000-0001-7694-6124
  • Marcé-Grau, Anna|||0000-0001-5762-4023
  • Ruiz Nel Lo, Anna
  • Martínez-Monseny, Antonio
  • Sánchez, Aurora|||0000-0003-1167-1451
  • García, Belén
  • Pérez-Dueñas, Belén|||0000-0002-4979-2788
  • Gel, Bernat|||0000-0001-8878-349X
  • Fusté, Berta
  • Hernández Ferrer, Carles
  • Casasnovas, Carlos|||0000-0002-7933-4681
  • Ortez González, Carlos Ignacio|||0000-0001-8187-8103
  • Arjona, César
  • Hernando Davalillo, Cristina
  • Natera de Benito, Daniel
  • Picó Amador, Daniel
  • Gómez-Andrés, David|||0000-0001-5654-7791
  • Yubero, Délia
  • Pelegrí-Sisó, Dolors|||0000-0002-5993-3003
  • Verdura, Edgard|||0000-0003-3856-2060
  • García Arumí, Elena|||0000-0003-1848-005X
  • Castellanos, Elisabeth|||0000-0002-8133-5325
  • Gabau, Elisabeth|||0000-0001-8120-7393
  • Tobías, Ester|||0000-0002-9968-3651
  • López-Grondona, Fermina
  • Cardellach, Francesc|||0000-0003-3286-3436
  • García García, Francesc Josep|||0000-0001-9021-0324
  • Munell Casadesus, Francina|||0000-0001-8580-2819
  • Tort, Frederic|||0000-0003-2733-1603
  • Aznar, Gemma
  • Olive Cirera, Gemma
  • Tell-Martí, Gemma|||0000-0003-2728-6961
  • Muñoz-Pujol, Gerard|||0000-0002-6863-3993
  • Paramonov, Ida
  • Blanco Guillermo, Ignacio|||0000-0002-7414-7481
  • Madrigal, Irene|||0000-0002-7229-1199
  • Valenzuela, Irene|||0000-0003-2350-6058
  • Gut, Ivo|||0000-0001-7219-632X
  • Cusco, Ivon|||0000-0003-2104-9332
  • Trotta, Jean-Rémi
  • Cruz, Jordi
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Milisenda, José César|||0000-0003-0151-7872
  • Ma Grau, Josep
  • Garcia-Villoria, Judit
  • Armstrong, Judith|||0000-0003-0588-9307
  • Cantó, Judith
  • Sala-Coromina, Júlia|||0000-0001-5116-6316
  • Rodríguez-Revenga, Laia
  • Alías, Laura|||0000-0003-2193-6185
  • Gort, Laura|||0000-0003-4746-1034
  • González Quereda, Lidia|||0000-0003-0715-6414
  • Costa, Mar
  • Fernández-Callejo, Marcos
  • López Sánchez, Marcos|||0000-0002-1517-5968
  • Álvarez Mora, María Isabel|||0000-0003-3788-8915
  • Gut, Marta|||0000-0002-4063-7159
  • Serrano, Mercedes|||0000-0002-2056-2428
  • Raspall-Chaure, Miquel|||0000-0002-3132-3342
  • Del Toro, Mireia|||0000-0002-8163-1853
  • Bayés, Mònica
  • Baena Díez, Neus|||0000-0003-0677-240X
  • Spataro, Nino|||0000-0002-2127-2238
  • Capdevila, Núria|||0000-0003-2080-7381
  • Ugarteburu, Olatz|||0000-0003-4214-3301
  • Muñoz-Cabello, Patricia|||0000-0002-5242-9605
  • Romero Duque, Penélope|||0000-0003-3509-1320
  • Rabionet, Raquel|||0000-0001-5006-8140
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Calvo-Escalona, Rosa|||0000-0001-9572-4228
  • Urreizti, Roser|||0000-0003-3617-7134
  • Bernal, Sara|||0000-0003-4427-0574
  • Boronat Guerrero, Susana|||0000-0001-7096-5578
  • Balcells, Susana|||0000-0003-1211-1907
  • Vendrell, Teresa
Many patients experiencing a rare disease remain undiagnosed even after genomic testing. Reanalysis of existing genomic data has shown to increase diagnostic yield, although there are few systematic and comprehensive reanalysis efforts that enable collaborative interpretation and future reinterpretation. The Undiagnosed Rare Disease Program of Catalonia project collated previously inconclusive good quality genomic data (panels, exomes, and genomes) and standardized phenotypic profiles from 323 families (543 individuals) with a neurologic rare disease. The data were reanalyzed systematically to identify relatedness, runs of homozygosity, consanguinity, single-nucleotide variants, insertions and deletions, and copy number variants. Data were shared and collaboratively interpreted within the consortium through a customized Genome-Phenome Analysis Platform, which also enables future data reinterpretation. Reanalysis of existing genomic data provided a diagnosis for 20.7% of the patients, including 1.8% diagnosed after the generation of additional genomic data to identify a second pathogenic heterozygous variant. Diagnostic rate was significantly higher for family-based exome/genome reanalysis compared with singleton panels. Most new diagnoses were attributable to recent gene-disease associations (50.8%), additional or improved bioinformatic analysis (19.7%), and standardized phenotyping data integrated within the Undiagnosed Rare Disease Program of Catalonia Genome-Phenome Analysis Platform functionalities (18%).
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Reducing the global burden of cerebral venous thrombosis, An international research agenda

  • Coutinho, Jonathan M.
  • van de Munckhof, Anita|||0000-0001-6028-3426
  • Aguiar de Sousa, Diana|||0000-0002-6702-7924
  • Poli, Sven
  • Aaron, Sanjith|||0000-0002-5151-1500
  • Arauz, Antonio
  • Conforto, Adriana B.
  • Krzywicka, Katarzyna
  • Hiltunen, Sini
  • Lindgren, Erik
  • Sánchez van Kammen, Mayte
  • Shu, Liqi
  • Bakchoul, Tamam
  • Belder, Rosalie
  • van den Berg, René
  • Boumans, Elisheva
  • Cannegieter, Suzanne
  • Cano-Nigenda, Vanessa|||0000-0002-8544-9717
  • Field, Thalia S.|||0000-0002-1176-0633
  • Fragata, Isabel
  • Heldner, Mirjam R.
  • Hernández-Pérez, María|||0000-0001-8279-7954
  • Klok, Frederikus A.|||0000-0001-9961-0754
  • Leker, Ronen R.|||0000-0003-4794-0334
  • Lucas-Neto, L.
  • Molad, Jeremy|||0000-0001-6868-4849
  • Nguyen, Thanh N.|||0000-0002-2810-1685
  • Saaltink, Dirk-Jan
  • Saposnik, Gustavo|||0000-0002-5950-9886
  • Sharma, Pankaj
  • Stam, Jan
  • Thijs, Vincent|||0000-0002-6614-8417
  • van der Vaart, Michiel|||0000-0003-0828-7088
  • Werring, David J.|||0000-0003-2074-1861
  • Wong Ramos, Diana
  • Yaghi, Shadi
  • Yeşilot, Nilüfer|||0000-0002-9655-9487
  • Tatlisumak, Turgut
  • Putaala, Jukka|||0000-0002-6630-6104
  • Jood, Katarina|||0000-0001-8746-1771
  • Arnold, M.
  • Ferro, José M.|||0000-0002-2343-9097
Background: Due to the rarity of cerebral venous thrombosis (CVT), performing high-quality scientific research in this field is challenging. Providing answers to unresolved research questions will improve prevention, diagnosis, and treatment, and ultimately translate to a better outcome of patients with CVT. We present an international research agenda, in which the most important research questions in the field of CVT are prioritized. Aims: This research agenda has three distinct goals: (1) to provide inspiration and focus to research on CVT for the coming years, (2) to reinforce international collaboration, and (3) to facilitate the acquisition of research funding. Summary of review: This international research agenda is the result of a research summit organized by the International Cerebral Venous Thrombosis Consortium in Amsterdam, the Netherlands, in June 2023. The summit brought together 45 participants from 15 countries including clinical researchers from various disciplines, patients who previously suffered from CVT, and delegates from industry and non-profit funding organizations. The research agenda is categorized into six pre-specified themes: (1) epidemiology and clinical features, (2) life after CVT, (3) neuroimaging and diagnosis, (4) pathophysiology, (5) medical treatment, and (6) endovascular treatment. For each theme, we present two to four research questions, followed by a brief substantiation per question. The research questions were prioritized by the participants of the summit through consensus discussion. Conclusions: This international research agenda provides an overview of the most burning research questions on CVT. Answering these questions will advance our understanding and management of CVT, which will ultimately lead to improved outcomes for CVT patients worldwide.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

NOTCH3 Variant Position Affects the Phenotype at the Pluripotent Stem Cell Level in CADASIL

  • bugallo, ana
  • Muiño, Elena
  • Hervella, Pablo
  • Arias-Rivas, Susana
  • Rodríguez-Yáñez, Manuel
  • Maisterra Santos, Olga
  • Pizarro Gonzálvez, Jesús
  • Bravo Lopez, Susana Belén
Disease modeling; Proteomic analysis; Stem cells, Modelització de malalties; Anàlisi proteòmica; Cèl·lules mare, Modelado de enfermedades; Análisis proteómico; Células madre, Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common genetic form of stroke. It is caused by a cysteine-altering variant in one of the 34 epidermal growth factor-like repeat (EGFr) domains of Notch3. NOTCH3 pathogenic variants in EGFr 1–6 are associated with high disease severity, whereas those in EGFr 7–34 are associated with late stroke onset and increased survival. However, whether and how the position of the NOTCH3 variant directly affects the disease severity remains unclear. In this study, we aimed to generate human-induced pluripotent stem cells (hiPSCs) from patients with CADASIL with EGFr 1–6 and 7–34 pathogenic variants to evaluate whether the NOTCH3 position affects the cell phenotype and protein profile of the generated hiPSCs lines. Six hiPSCs lines were generated: two from patients with CADASIL with EGFr 1–6 pathogenic variants, two from patients with EGFr 7–34 variants, and two from controls. Notch3 aggregation and protein profiles were tested in the established six hiPSCs lines. Cell analysis revealed that the NOTCH3 variants did not limit the cell reprogramming efficiency. However, EGFr 1–6 variant position was associated with increased accumulation of Notch3 protein in pluripotent stem cells and proteomic changes related with cytoplasmic reorganization mechanisms. In conclusion, our analysis of hiPSCs derived from patients with CADASIL support the clinical association between the NOTCH3 variant position and severity of CADASIL., This study has been funded by Instituto de Salud Carlos III (ISCIII) through the project PI17/00540, PI20/01014, PI23/000890, RICORS-ICITUS RD21/0006/0003, RD21/0006/0004, RD24/0009/0022, RD24/0009/0017 and AC23-2/00029. AC23-2/00029 (named as CADANHIS) project has been supported by the EJP RD—European Joint Programme on Rare Diseases—Joint Transnational Call 2023 for Rare Diseases Research Project (JTC 2023). The EJP RD initiative has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement N°825575. Finally, this work was supported by grants from the Instituto de Salud Carlos III, PReDICT Project (PMPER24/00021) together with Next-Generation EU funds that finance the actions of the Recovery and Resilience Mechanism.